COMPOSITIONS AND METHODS FOR WOUND HEALING

Abstract

Mice in which enhance wound healing occurs can be used to identify genes and gene products which are involved in enhanced wound healing in mammals, including humans. Methods and compositions for treating wounds, including central and peripheral nerve wounds, are also provided.

Description

TECHNICAL FIELD OF THE INVENTION

[0003] This invention is related to the field of wound healing. More particularly, the invention is related to methods and compositions for enhancing wound healing in mammals.

BACKGROUND OF THE INVENTION

[0004] The biological response to tissue injury in higher organisms falls into two main categories: wound repair and regeneration (1). In amphibians, the form of wound healing seen is often epimorphic regeneration, where entire limbs can be reformed after amputation (1). In adult mammals, wound healing can involve wound repair or tissue regeneration, including the replacement of mature cells through cell proliferation (7) or replenishment of cells, but not organs, from immature stem cells (9, 11, 25). Complete wound healing, however, with perfect replacement of tissue and function, is typically not observed. Injuries to the central and peripheral nervous system, including optic nerve and spinal cord injuries, are especially refractory to healing. Thus, there is a need in the art for methods and compositions for enhancing wound healing in mammals.

SUMMARY OF THE INVENTION

[0005] It is an object of the invention to provide methods and compositions for use in healing wounds. These and other objects of the invention are provided by one or more of the embodiments described below.

[0006] One embodiment of the invention is a method of identifying a gene involved in enhanced wound healing. DNA microsatellite markers which can distinguish a first and a second mouse strain are identified. The first mouse strain is a healer mouse strain, and the second mouse strain is not a healer mouse strain. Microsatellite markers which segregate with enhanced wound healing in progeny of the first and second mouse strains are identified. A chromosomal locus which contains at least one gene involved in enhanced wound healing is thereby identified.

[0007] Still another embodiment of the invention is a method of treating a wound in a mammal. A reagent which specifically binds to an expression product of a gene whose expression is decreased in a healer mouse relative to a non-healer mouse is administered to a mammal with a wound. Expression of the gene is thereby decreased.

[0008] Even another embodiment of the invention is a method of treating a wound in a mammal. An expression product of a gene whose expression is increased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse is administered to a mammal with a wound. The level of the expression product in the wound is thereby increased.

[0009] Yet another embodiment of the invention is a method of restoring function after nerve injury in a mammal. A reagent which specifically binds to an expression product of a gene whose expression is decreased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse is administered to a mammal with a nerve injury. Expression of the gene is thereby decreased.

[0010] Another embodiment of the invention is a method of restoring function after nerve injury in a mammal. An expression product of a gene whose expression is increased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse is administered to a mammal with a nerve injury. The level of the expression product in the wound is thereby increased.

[0011] Still another embodiment of the invention is a method of treating a wound in a mammal. A cell or cellular extract obtained from a healer mouse is administered to a mammal with a wound. Healing of the wound in the mammal is thereby enhanced.

[0012] Yet another embodiment of the invention is a method of treating a wound in a mammal. A cell in which expression of a wound healing gene has been altered is administered to a mammal with a wound. Healing of the wound in the mammal is thereby enhanced.

[0013] Even another embodiment of the invention is a healer mouse having at least one quantitative trait locus selected from the group consisting of the quantitative trait loci shown in Tables 2, 9 and 16. The healer mouse exhibits an enhanced healing response to a wound compared to a mouse which does not have the at least one chromosomal locus. The healer mouse is not an MRL mouse.

[0014] Yet another embodiment of the invention is a preparation comprising a fraction of an extract of a tissue of a healer mouse. The preparation alters a biological property of a model of wound healing.

[0015] Still another embodiment of the invention is a preparation comprising cells of a healer mouse. The preparation alters a biological property of a model of wound healing.

[0016] Another embodiment of the invention is a method of identifying a factor involved in enhanced wound healing. A model of wound healing is contacted with a preparation selected from the group consisting of serum, a fraction of serum, an extract of at least one healer mouse tissue, and a fraction of an extract of at least one healer mouse tissue. A property of the model of wound healing is assayed. A preparation which alters the property of the model of wound healing is identified as comprising a factor involved in enhanced wound healing.

[0017] Yet another embodiment of the invention is a method of screening test compounds for the ability to enhance wound healing. A healer model of wound healing is contacted with a test compound. The healer model comprises cells of a healer mouse. The effect of the test compound on a biological property associated with wound healing is measured in the healer model. A test compound which enhances the biological property of the healer model is identified as a potential factor for enhancing wound healing.

[0018] The present invention thus provides the art with a mammalian model of enhanced wound healing. The healer mouse described herein can be used, inter alia, to identify genes and gene products involved in enhanced wound healing and to provide methods and compositions for healing wounds, particularly wounds of the nervous system, in mammals.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIG. 1. The kinetics of ear punch hole closure. Two mm holes were punched in ears on day 0 and, for each strain of mouse, holes were measured at days indicated on the horizontal axis. Average hole diameters are shown (n=4).

[0020] FIG. 2. Photographs of the healing ear wounds. C57BL/6 (left side) and MRL/1pr (right side) ears were punched bilaterally in the center of the ears creating a 2 mm through-and-through wound and followed for 33 days. The ear holes of the C57BL/6 mouse remained open 1 day (FIG. 2A), 9 days (FIG. 2B), 20 days (FIG. 2C), and 33 days (FIG. 2D) after punching. In the MRL/1pr mouse, one can see the progression of hole closure from day 1 (FIG. 2E), day 9 (FIG. 2F), day 20 (FIG. 2G), to day 33 (FIG. 2H).

[0021] FIG. 3. Histological examination of early events in ear hole closure. The first two days after wounding of C57BL/6 ears (FIGS. 3A and 3D) and MRL/+ (FIGS. 3B and 3E) and MRL/1pr ears (FIGS. 3C and 3F) were examined. Day 1: these sections show more swelling at the wound site for the MRL tissue (smaller arrows). Eschar and inflammatory cellular infiltrate at the wound margin is similar for both strains and re-epithelialization is not seen (larger arrows). Day 2: The C57BL/6 wound is partially covered (arrow) by eschar with migrating epithelium not yet covering the wound (9 out of 14 edges examined did not close) while the MRL wound is completely covered (arrows) with epithelium (10 out of 14 edges examined completely closed). Magnification=40×; tissue is stained with hematoxylin and eosin.

[0022] FIG. 4. Day 5, 10, and 20 wounds. For all days indicated for C57BL/6 tissue (A), MRL/+ tissue (B) and MRL/1pr tissue (C). All sections are stained with hematoxylin and eosin (pictures are representative of 4 edges examined). FIG. 4A. Day 5 (A, B, C: 40×-upper panels and 20×-lower panels): Swelling at the MRL wound site is extensive with neovascularization (40×-arrows) and marked dermal fibroblast proliferation (20×-large arrows). Adnexae in the new epithelium can be seen here (20×-small arrows). A C57BL/6 wound that has failed to epithelialize is shown here, although this is not typical (20×-*). FIG. 4B. Day 10 (A, B, C: 40×-upper panels and 10×-lower panels): There is marked neovascularization (40×-arrows) and fibroblast proliferation (10×-arrows) seen in the MRL wound extending out beyond the borders of the wound where the cut cartilage edges are seen. Note the extent to which dermal cells have migrated out beyond the wound margin marked by the cartilage edge for the two MRL ears compared to the C57BL/6 ear. FIG. 4C. Day 20 (A, C:20×; B:40×-upper panels and 5×-lower panels): The prominent proliferation of fibroblasts in the dermis and the appearance of a blastema-like structure has led to significant closure of the MRL wound as originally marked by the cut edges of cartilage at the right and left margins of the photograph (5×-between arrows). By comparison, there is little extension of C57BL/6 tissue into the wound space. The homogeneity of fibroblast proliferation and ECM deposition is most striking in MRL (B:40×-upper panel).

[0023] FIG. 5. Late-stage ear wound closure. Wound sites (n=3) 81 days after wounding for C57BL/6 (top) and MRL/1pr (bottom) mice were aligned using a dissection microscope and sutured together to assure sectioning through the former wound for MRL/1pr tissue. Cartilagenous islands (small arrow) present throughout the MRL/1pr section are surrounded by prominent adipocytes (large arrow). These features are absent from the C57BL/6 tissue. The tissue sections are stained with Gomori trichrome. Magnification=10×.

[0024] FIG. 6. The analysis of frequencies of wound closure on day 30 in parental and crossbred populations. Histograms of day 30 ear punch hole diameters can be seen for the following genotypes: C57BL/6 and MRL/1pr parental mice and F1 mice (upper panel) and the first backcross to each parental strain (lower panel).

[0025] FIG. 7. Histogram of wound closure in (MRL/1pr×C57BL/6)F1 and F2 intercross populations.

[0026] FIG. 8. Additive effects of heal1 and heal3 on wound closure. Average residual wound diameters are plotted for each genotype, with the results grouped by D13Mit129 and D8Mit211. The mean of all F2 mice ±1 s.e.m. is depicted as a horizontal line in this graph. B, H, and S designate mice homozygous for the heal b/ballele from C57BL/6, heterozygous for the healb/s alleles from C57BL/6 and MRL/1pr, or homozygous for the heals/s allele from MRL/1pr, respectively.

[0027] FIG. 9. Healer and non-healer mice 1.5 months after transection of the left optic nerve. FIG. 9A. The non-healer (B6) mouse exhibits complete atrophy of the left eye with marked sinking of the left eye socket compared to the normal untreated right eye. FIG. 9B. The healer (MRL) mouse exhibits only slight sinking of the left eye compared to the normal, untreated right eye.

[0028] FIG. 10. Images depicting histological longitudinal sections of the healer (MRL) mouse uncut right eye-specific tissue. These serial sections were stained with hematoxylin and eosin.

[0029] FIG. 11. A series of images depicting histological longitudinal sections of the healer (MRL) mouse cut left eye-specific tissue. These serial sections were stained with hematoxylin and eosin.

[0030] FIG. 12. FIG. 12A is an image depicting a histological longitudinal section of the healer (MRL) mouse normal uncut right eye-specific tissue. This section was stained with Bodian's silver stain specific for axons. FIG. 12B is an image depicting a histological longitudinal section of the healer (MRL) mouse cut left eye-specific tissue. This section was stained with Bodian's silver stain specific for axons. The blue arrows indicate nerve fibers and the red arrows point to oligodendrocytes.

[0031] FIG. 13. Graph depicting nerve regeneration in various strains of mice. SFI, Sensory Function Index.

[0032] FIG. 14. Graph depicting healing of ear holes in LG mice.

[0033] FIG. 15. Graph depicting adoptive transfer of the healing ability of MRL mice, wherein macrophages obtained from healer mice were transferred to non-healer mice.

[0034] FIG. 16. Results from microarray analysis of gene expression in MRL mice after ear punch. Series 1, no ear punch; Series 2, 24 hours after ear punch; Series 3, 40 hours after ear punch. Names of genes are given in Table 11.

[0035] FIG. 17. Graph showing the effect of age on the time course of ear hole closure in healer mice.

[0036] FIG. 18. Graph demonstrating that T cell depletion leads to complete healing in aged healer mice.

[0037] FIG. 19. Bar graph demonstrating that T cell receptor knock-outs show enhanced healing.

[0038] FIG. 20. Bar graph showing that adoptive transfer of fetal liver into X-irradiated non-healer recipients enhances wound healing.

[0039] FIG. 21. Two-day old explant cultures of punched ears of healer and non-healer mice. FIG. 21A, explant of a healer mouse ear punch. FIG. 21B, magnified view of the healer mouse ear punch explant. FIG. 21C, explant of a non-healer mouse ear punch. FIG. 21D, magnified view of the non-healer ear punch explant.

[0040] FIG. 22. Magnified view of the area around a healer mouse ear punch explant, demonstrating migration of cells away from the explant.

[0041] FIG. 23. Graph demonstrating that adoptive transfer of bone marrow-derived dendritic cells into ear-punched C57BL/6 Rage immunodeficient mice enhances wound healing.

DETAILED DESCRIPTION

[0042] It is a discovery of the present invention that healer mice, including MRL mice and strains derived from MRL mice, can be used as murine models of wound healing, particularly of the central and peripheral nervous system. These models are useful for identifying genes and gene products which are involved in enhanced wound healing in mammals, including humans, as well as for developing therapeutic compounds and methods to enhance wound healing.

[0043] Healer Mice

[0044] Typically, holes punched in the ears of non-healer mice are permanent and exhibit at most about 25% closure even 60 days after punching. Patterns of such holes can thus be used to distinguish individual non-healer mice from one another, which is a standard laboratory method for animal identification. In contrast, a hole punched in the ear of a healer mouse will close at least 70%, more preferably at least 80% or 90%, within 60 days, more preferably within 45 or 30 days. Most preferably, an ear hole of a healer mouse closes completely.

[0045] The percent closure of a hole punched in the ear of a mouse can be determined by measuring the initial diameter of the hole and by taking subsequent measurements during the first thirty days after punching. Typically, a 2 mm hole is punched. In particularly preferred healer mouse strains, complete ear hole closure occurs 30 days after punching, without scar tissue and with regeneration (perfect replacement) of cell types initially present in the ear, such as cartilage, dermis, epidermis, and blood vessels.

[0046] The healing capacity of a mouse strain can easily be tested by an ear punch assay, as described above. However, healing capacity can be assessed following other types of wounds in the mouse, including, but not limited to, digit cutting, tail cutting, and cutting or crushing of a nerve, particularly an optic or sciatic nerve, or a partial or complete cutting or crushing of the spinal cord. Liver regeneration can also be measured.

[0047] In addition to ear hole closure as described above, a mouse strain with a healer phenotype, in contrast to a non-healer mouse, may also exhibit one or more of the following characteristics. All such aspects of the healer phenotype, including enhanced tissue regeneration, are components of enhanced wound healing. Blastemas may form in the vicinity of a cut in the ear, digits, tail, or liver in a strain of healer mouse. Following injury to the liver, a strain of healer mouse may exhibit rapid replacement of liver mass and homeostasis. A healer mouse strain may exhibit breakdown in the extracellular matrix-basement membrane to allow epithelial-mesodermal interaction and may express forms of extracellular matrix-basement membrane components, such as tenascin, which are typically expressed only during development or regeneration. Organ regeneration can also occur.

[0048] Healer mouse strains may also exhibit rapid recovery from central or peripheral nerve damage, such as sciatic or optic nerve crush, or cutting or crushing of the spinal cord, and can thus be used as models in which to study regeneration of injured nerves. Nerve regeneration can be detected using functional assays appropriate for the particular nerve involved, such as electrical stimulation of the nerve and detection of contraction of the reinnervated muscle, or can be detected by observing restoration of normal neuronal architecture as a precursor to reacquisition of complete or partial normal function. In preferred healer mouse strains, regrowth and connection occurs after complete transection of nerves of the central or peripheral nervous system. Most preferably, healer mice exhibit maintenance of the optic nerve and eye with no accompanying degeneration of either structure following injury, such as crushing or transection, of the optic nerve. In addition, neurites regrow in the proper direction through a cut region of the optic nerve, and glial cells, such as oligodendrocytes, reappear in the injured area. After cutting or crushing of the spinal cord at the thoracic level, for example, preferred strains of healer mice recover at least partial function in their hind limbs and tail.

[0049] Healer mouse strains can be naturally occurring or can be generated, for example, by traditional genetic crossings, by transgenic manipulation, or by mutagenic techniques, as is known in the art. One strain of healer mouse is the MRL mouse. The MRL mouse (H-2k) is derived from an interbreeding of the LG mouse (75%; H-2d/f), the AKR mouse (12.6%; H-2k); the C3H mouse (12.1% h-2k) and the C57B1/6 mouse (0.3%; H-2b) (13) and was selected originally for its large size. A mutant derived from this colony, MRL/1pr showed enlarged spleen and lymph nodes with age, lymphoproliferation with aberrant control of apoptosis in germinal centers, and a high susceptibility to autoimmune disease with autoantibodies, an arthritis-like syndrome, and glomerulonephritis. This was shown to be the direct result of a retrotransposon insertion into the second intron of the fas gene in the 1pr strain (16, 17,23). However, the rapid and complete wound closure described here is unrelated to fas since the MRL/+ mouse has the same healing characteristics. Furthermore, wound closure is unlinked to the lympadenopathy (R=0.4) associated with 1pr mice and the autoantibodies made to histone proteins by these animals (13-15, 24). This lack of fas involvement has been confirmed in mapping studies using MRL/1pr and C57BL/6 backcross mice showing a clear genetic basis for this regeneration trait, unlinked to the fas genetic locus (McBrearty et al., Proc. Natl. Acad. Sci. U.S.A. 95, 11792-97, 1998). One characteristic of the MRL mouse is its large size, but there is no evidence that this trait is linked to adult body weight (R=0.12).

[0050] Other preferred strains of healer mice can be generated by crossing a healer mouse, such as an MRL mouse, with a non-healer mouse, such as a C57BL/6 mouse, and selecting progeny (F1) mice which display a healer phenotype. F1 healer mice can be intercrossed to form an F2 generation, in which mice with a healer phenotype can be identified. Alternatively, a male or female F1 healer mouse can be back-crossed with a female or male mouse of its healer or non-healer parent strain. The progeny of any of these crosses which display a partial or a complete healer phenotype are healer mice according to the invention. Other non-healer mouse strains, such as 129, can be crossed with a non-healer strain such as C57BL/6 to form healer mouse strains. Characteristics of the healer phenotype are those which are described above.

[0051] Mutagenic techniques, including but not limited to, targeted and non-targeted chemical mutagenesis using agents such as DMBA and ENU, as well as irradiation, for example with UV light or X-rays, can be used to induce mutations in one or more genes involved in enhanced wound healing to form a healer phenotype. Genes which can be mutated include, but are not limited to, the genes disclosed herein in Tables 4-11, 14, 15, and genes comprising the SAGE tags disclosed in Tables 12 and 13, as well as genes which regulate them.

[0052] It is also possible to create healer mouse strains using transgenic manipulations, to create transgenic, knock-in, or knock-out mice in which the function of one or more genes involved in the enhanced healing response is altered to achieve a healer phenotype. The genes of Tables 4-11, 14, 15, and genes comprising the SAGE tags disclosed in Tables 12 and 13, as well as genes which regulate them, are candidates for such manipulation. Conditional knock-in or knock-out mice, which will express one or more wound healing genes at a designated developmental stage or under particular environmental conditions, can also be constructed. Methods of creating transgenic, knock-in, and knock-out mice are well-known in the art. (See, e.g., U.S. Pats. No. 5,464,764 and 4,873,191).

[0053] Identification of Wound Healing Factors

[0054] Healer mice can also be used to identify factors which promote wound healing, particularly recovery from central or peripheral nerve injury, as well as genes which encode the factors. Either in vitro or in vivo models of wound healing can be used for this purpose. In vitro models can comprise tissue explants or cells. For example, all or a portion of an ear comprising a cut or a punch wound can conveniently be maintained as an explant in a collagen gel. Explants of other tissues, such as skin and nerve tissue, can also be used. Methods of maintaining tissue explants are well known in the art.

[0055] Mammalian cell lines or primary cultures of mammalian cells can also be used as in vitro models of wound healing. Suitable cell types include, but are not limited to, epidermal, mesodermal, cartilage, muscle, neuronal, glial, macrophage, and liver cells or cell lines. Many such cell lines can be obtained from commercial sources such as the American Type Culture Collection. Primary cells can be isolated from mammals such as mice, rabbits, rats, pigs, hamsters, monkeys, or humans. Methods of maintaining such cells in vitro as monolayers, suspension cultures, or cellular reaggregates are also well known.

[0056] Alternatively, the model can be a mammal, such as a rat or mouse, which has a wound. The wound can be, for example, a cut or abrasion in the skin, a tail or ear cut or an ear punch, a cut in the liver, or a severed or crushed nerve, including an optic nerve or spinal cord.

[0057] The effects of partially or fully purified proteins or nucleic acids, whole cells, such as macrophages or fibroblasts, or tissue extracts, including serum, obtained from healer mice can be tested in the in vitro or in vivo model of wound healing. Regeneration of the tissues and cells and/or morphological or biochemical changes associated with wound healing can be assessed and compared with those processes in the absence of added proteins, cells, or tissue extracts obtained from healer mice or in the presence of proteins, cells, or extracts obtained from non-healer mice. Cells such as fibroblasts, macrophages, and nerve cells isolated from healer and non-healer mice can be treated with cells, serum, or cell extracts from either non-healer or from healer mice.

[0058] Properties of a wound healing model which can be assessed include, but are not limited to, enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell replication, cell movement, cell adhesion, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability. Methods of assessing these properties include morphological assessment, either with or without the aid of a microscope, as well as biochemical and molecular biology methods well-known in the art. The alteration of at least one of these properties or of another property associated with enhanced wound healing or tissue regeneration, including an alteration in the time course of an effect, identifies a factor involved in these processes.

[0059] Extracts can be prepared from tissues and cells of healer mice using standard tissue disruption techniques, such as sonication, passage through a French press, Dounce homogenization, blending, Polytron disruption, enzymatic digestion, or blending with glass beads, followed by centrifugation. If desired, an extract can be divided into one or more fractions to further identify particular factors involved in enhanced wound healing. Any known method of fractionation, including fractional precipitation with ammonium sulfate, polyethylene glycol, or organic solvents, gel permeation or gel filtration chromatography, ion exchange chromatography, hydrophobic chromatography, dye-ligand affinity chromatography, bio-ligand affinity chromatography, high performance liquid chromatography, fast-flow liquid chromatography, electrophoretic separation methods, and the like, can be used, as is convenient.

[0060] Extracts or fractions of extracts which cause an alteration in an in vitro model or which enhance wound healing in an explant or an in vivo model can be purified by biochemical, molecular biological, and/or immunological means using standard technology or can be identified, for example, by selective inactivation. Methods such as two-dimensional gel electrophoresis can also be used to identify proteins which are present or absent, or which are present in different amounts in healer mice compared with non-healer mice. The effects of a purified factor can be confirmed using either an in vitro or an in vivo model of wound healing, as described above.

[0061] Alternatively, a subtractive hybridization-type approach can be used to identify factors capable of enhancing wound healing or tissue can be obtained from healer mice, and mRNA can be extracted from these cells using methods well known in the art. Specific mRNAs which are expressed in the cells of healer mice can be isolated by subtractive hybridization of healer mRNA with mRNA obtained from identical cells from non-healer mice. Differentially expressed mRNAs can then be reverse transcribed to form cDNA.

[0062] Genes encoding such factors may then be identified, cloned, sequenced and otherwise characterized, as is known in the art. cDNA can be cloned into an expression vector using standard methodologies. Protein expressed from the cDNA can be tested for the ability to enhance wound healing or tissue regeneration of mammalian tissue in an in vitro or in vivo model such as those described above. cDNA which encodes a protein identified as involved in enhanced wound healing can be sequenced and further characterized as desired using ordinary molecular biology technology. The technology required to perform these experiments is well known in the art and is described, for example, in Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor Laboratory, New York, 1989) and in Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Green & Wiley, New York, 1993).

[0063] Any murine wound healing factors which are identified using a healer mouse can be used to identify counterpart factors in other mammals, particularly in humans. For example, degenerate primers encoding portions of murine wound healing factors can be constructed and used to probe cDNA libraries of other mammalian species, preferably human cDNA libraries. Antibodies which specifically bind to a murine wound healing factor can be used to identify similar factors in cells, tissues, extracts, or expression libraries of other mammalian species, preferably human. Thus, the invention should be construed to include the identification of any and all mammalian wound healing factors which share homology with those identified in the murine systems described herein.

[0064] The invention also provides methods of screening test compounds for the ability to enhance wound healing. The test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art. Members of combinatorial libraries can also be screened for wound healing activity.

[0065] A healer model of wound healing is contacted with a test compound. The healer model comprises cells of a healer mouse, and can be any of the in vitro or in vivo types of wound healing models described above. Healer models in which healer and non-healer cells are mixed can also be used. The effect of the test compound on a biological property associated with wound healing is measured in the healer model. These biological properties include, but are not limited to, enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell replication, cell movement, cell adhesion, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability. A test compound which enhances the biological property of the healer model is identified as a potential factor for enhancing wound healing.

[0066] Optionally, the effect of the test compound on the biological property of the healer model can be compared with its effect on the same or a similar biological property of a non-healer model of wound healing. Non-healer models are any of the in vitro or in vivo models described above, but do not comprise healer mouse cells. A test compound which alters the biological property of the non-healer model such that it resembles the biological property of the healer model is identified as a potential factor for enhancing wound healing.

[0067] Identification of Healer Chromosomal Loci and Genes

[0068] Healer mice are particularly useful for identifying genes which are differentially expressed in healer vs. non-healer mice and which are involved in enhanced wound healing. Wound healing genes include genes whose products are directly involved in enhanced wound healing or tissue regeneration, as well as genes which regulate them. Such genes can be identified by a variety of methods. For example, differentially expressed wound healing genes can be identified based on microarray, SAGE, and RT-PCR analyses, as described in the Examples, below.

[0069] Chromosomal loci which contain at least one gene which encodes a protein involved in enhanced wound healing can be identified by genome screening. DNA microsatellite markers are identified which can distinguish two strains of mice. One of the two strains is a healer mouse strain, such as the MRL mouse or its progeny The other strain is a non-healer mouse, such as a C57BL/6. A number of suitable mouse strains are available commercially, for example from Jackson or Taconic Laboratories. Microsatellite markers which segregate with enhanced wound healing in progeny of the two strains identify a chromosomal locus which contains at least one gene which is involved in enhanced wound healing. The product of this gene may be directly involved in enhanced wound healing or may regulate expression of another gene which is involved in enhanced wound healing. This method is described in detail in Examples 3-7, below.

[0070] Certain quantitative trait loci identified by this method can be observed to segregate with either male or female healer mice. For example, the quantitative trait loci identified on chromosome 7 segregate with male mice, as do some of the quantitative trait loci on chromosome 13. In addition, quantitative trait loci identified on chromosomes 4 and 18 segregate with male mice. On the other hand, the quantitative trait loci identified on chromosomes 12 and 15 segregate with female mice.

[0071] Congenic mouse strains, created by successive back-crossings of the F1 generation of a healer x non-healer cross with its non-healer parent strain and selected for a healer phenotype, are especially useful for identifying chromosomal loci which segregate with the healer phenotype. The healer phenotype of such congenic healer mice ranges from mice with the ability to heal a 2 mm ear hole at least 75% to mice which heal such ear holes completely. For example, after six successive back-crossings, a healer mouse strain was identified which retains approximately 2% of the markers of the healer mouse genome, including the quantitative trait loci shown in Tables 2 , 9, and 16, and which exhibits a healer phenotype (Example 19 and Table 16). By repeated back-crossings, strains of healer mice can be created which have at least one of the quantitative trait loci shown in Tables 2, 9, and 16. One locus of particular interest is marker 39, located at 29 cM on chromosome 16. This locus coincides with the location of a wound healing gene termed p63, located between 14 and 29 cM on chromosome 16.

[0072] A number of genes involved in enhanced wound healing or tissue regeneration have been identified using these methods. Genes which are differentially expressed between healer and non-healer mouse dendritic cells are shown in Table 15. Genes whose expression is differentially increased or decreased in healer mice after wounding, such as ear punching, are shown in Tables 5, 6, 7, 8, 10, 11, and 15. Levels of some gene products, such as ezrin, c-Jun, and c-myc, are increased in both males and females. Levels of other gene products, such as PI-K p58, and glutathione s-transferase, are decreased in both males and females after wounding.

[0073] Still other gene products show more complex changes after wounding, being altered only in males or females, at early or late stages after wounding, or a combination of both. For example, the hox8 (msx2) gene is over-expressed in healer mice at 0, 1, and 5 days after ear punch, but its expression decreases at about 20 days after ear punch, when the ear begins to heal.

[0074] Therapeutic Methods for Treating Wounds

[0075] Manipulation of the expression of wound healing genes in non-healer mammals, including altering effective levels of their expression products, in non-healer mammals can be used to treat wounds and to enhance or promote wound healing, particularly in humans.

[0076] Wounds can be treated at early or late stages after wounding by selectively manipulating expression of particular wound healing genes. Certain of these genes are identified in Tables 5, 6, 7, 8, 10, 11, and 15. Optionally, expression of one or more wound healing genes can be manipulated simultaneously or sequentially. Furthermore, wounds in males or females can be treated most effectively by selecting the appropriate wound healing genes for manipulation.

[0077] Expression of genes of Tables 5, 6, 7, 8, 10, 11, and 15 whose expression is selectively decreased and/or increased in healer mice at particular times after wounding can be manipulated in order to enhance wound healing. Particularly preferred genes are msx2 and RARg. Any method known in the art can be used to decrease or increase expression of a wound healing gene. Methods of decreasing effective expression of a wound healing gene include, but are not limited to, use of ribozyme, antisense, or antibody technologies. Methods of increasing effective expression of a wound healing gene include, but are not limited to, providing polynucleotide sequences encoding expression products of the gene such as protein or mRNA, as well as providing the expression products themselves.

[0078] In one embodiment of the invention, expression of a wound healing gene is altered using an antisense oligonucleotide sequence. The antisense sequence is complementary to at least a portion of the coding sequence of the gene. The coding sequences of preferred wound healing genes can be obtained from databases such as Genbank; accession numbers for some of thtese genes are provided in Table 14. Preferably, the antisense oligonucleotide sequence is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences can also be used. Antisense oligonucleotide molecules can be provided in a construct and introduced into cells using standard methodologies to decrease expression of one or more wound healing genes.

[0079] Antibodies which specifically bind to a wound healing protein can also be used to alter the effective expression levels of a wound healing gene. Wound healing-specific antibodies bind to a wound healing protein and prevent the protein from functioning in the cell. Preparations of polyclonal and monoclonal antibodies can be made using standard methods. Antibody fragments such as Fab, single-chain Fv, or F(ab′)2 fragments can also be prepared. If desired, antibodies and antibody fragments can also be “humanized” in order to prevent a patient from mounting an immune response against the antibody when it is used therapeutically, as is known in the art. Other types of antibodies, such as chimeric antibodies, can be constructed as disclosed, for example, in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the “diabodies” described in WO 94/13804, can be prepared and used in methods of the invention. Anti-idiotype antibodies, directed against unique sequence variants in wound healing gene products, can also be used in therapeutic methods of the invention.

[0080] Useful antibodies specifically bind to epitopes present in proteins encoded by a wound healing gene. The amino acid sequences of these proteins are available from Genbank (see, e.g., Table 14 for accession numbers). Antibodies which specifically bind to wound healing proteins provide a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in Western blots or other immunochemical assays. Preferably, antibodies which specifically bind to a wound healing protein do not detect other proteins in immunochemical assays and can immunoprecipitate the wound healing protein from solution.

[0081] Antibodies can be purified by methods well known in the art. For example, the antibodies are affinity purified, by passing the antibodies over a column to which a wound healing protein is bound. The bound antibodies can then be eluted from the column, for example, using a buffer with a high salt concentration.

[0082] Ribozymes can be used to inhibit gene function by hybridizing to and cleaving an RNA sequence of a wound healing mRNA, as is known in the art (e.g., Haseloff et al., U.S. Pat. No. 5,641,673). The nucleotide sequences of wound healing genes, available from databases such as Genbank (see Table 14), are sources of suitable hybridization region sequences.

[0083] Preferably, the mechanism used to decrease the effective expression of the involved gene decreases levels of gene expression products, such as mRNA or protein, by 50%, 60%, 70%, or 80%. Most preferably, effective expression of the gene is decreased by 90%, 95%, 99%, or 100%. Effective expression of the involved gene can be assessed using methods well known in the art, such as hybridization of nucleotide probes to mRNA of a wound healing gene, quantitative RT-PCR, or detection of wound healing protein using specific antibodies.

[0084] Expression of wound healing genes whose expression is increased in healer mice after wounding can be effectively increased in a non-healer mammal in order to enhance wound healing. Any method known in the art for enhancing gene expression can be used for this purpose. For example, the coding sequence of one or more wound healing genes can be delivered to cells in the vicinity of a wound. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce the coding sequence into cells in which it is desired to increase wound healing gene expression. Alternatively, if it is desired that the cells stably retain the construct, it can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. The construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of the coding sequence in the cells.

[0085] Vectors, such as retroviral- or adenoviral-based vectors, can be used for this purpose. Recombinant retroviruses are described in numerous references, including Mann et al., Cell 33:153, 1983, Cane and Mulligan, Proc. Nat'l. Acad. Sci. USA 81:6349, 1984, Miller et al., Human Gene Therapy 1:5-14, 1990, and U.S. Pat. Nos. 4,405,712, 4,861,719, and 4,980,289.

[0086] Advenoviral vectors are preferred. The use of adenoviral vectors in vitro is described in Chatterjee et al., Science 258: 1485-1488 (1992), Walsh et al., Proc. Nat'l. Acad. Sci. 89: 7257-7261 (1992), Walsh et al., J. Clin. Invest. 94: 1440-1448 (1994), Flotte et al., J. Biol. Chem. 268: 3781-3790 (1993), Ponnazhagan et al., J. Exp. Med. 179: 733-738 (1994), Miller et al., Proc. Nat'l Acad. Sci. 91: 10183 -10187 (1994), Einerhand et al., Gene Ther. 2: 336-343 (1995), Luo et al., Exp. Hematol 23: 1261-1267 (1995), and Zhou et al., Gene Therapy 3: 223-229 (1996). In vivo use of adenoviral vectors is described in Flotte et al, Proc. Nat'l Acad. Sci. 90: 10613-10617 (1993), and Kaplitt et al., Nature Genet. 8:148-153 (1994). Other viral vectors, such as those based on togaviruses or alpha viruses, can also be used.

[0087] A wound healing coding sequence can also be combined with a condensing agent, such as polylysine, polyarginine, polyornithine, protamine, spermine, spermidine, or putrescine, to form a gene delivery vehicle. Many suitable methods for making such linkages are known in the art. Alternatively, a wound healing coding sequence can be associated with a liposome to deliver the coding sequence to cells at the site of the wound. Other suitable methods of providing wound healing coding sequences include DNA-ligand combinations, such as those disclosed in Wu et al., J. Biol. Chem. 264:16985-16987 (1989). Wound healing coding sequences can also be delivered to the site of an internal wound, for example, using receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis et al. Trends in Biotechnol. 11,202-05 (1993); Chiou et al., GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J. A. Wolff, ed.) (1994); Wu & Wu, J. Biol. Chem. 263, 621-24 (1988); Wu et al., J. Biol. Chem. 269, 542-46 (1994); Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87, 3655-59 (1990); Wu et al., J. Biol. Chem. 266, 338-42 (1991). Expression of a wound healing gene can be monitored by detecting production of mRNA which hybridizes to a delivered coding sequence or by detecting the protein product of the gene using, for example, immunological techniques.

[0088] Expression of an endogenous wound healing gene in a cell can also be altered by introducing in frame with the endogenous gene a DNA construct comprising a targeting sequence, a regulatory sequence, an exon, and an unpaired splice donor site by homologous recombination, such that a homologously recombinant cell comprising a new transcription unit is formed. The new transcription unit can be used to turn the wound healing gene on or off as desired. This method of affecting endogenous gene expression is taught in U.S. Pat. No. 5,641,670, which is incorporated herein by reference.

[0089] The targeting sequence is a segment of at least 10, 15, 20, or 50 contiguous nucleotides selected from the nucleotide sequence of a wound healing gene. The nucleotide sequences of the wound healing genes disclosed herein are available, for example, from Genbank, using the accession numbers provided in Table 14. The transcription unit is located upstream of a coding sequence of the endogenous wound healing gene. The exogenous regulatory sequence directs transcription of the coding sequence of the wound healing gene.

[0090] Optionally, effective expression of one or more wound healing genes can be altered in cells which have been removed from a mammal, such as dermal fibroblasts or peripheral blood leukocytes. The cells can then be replaced into the same or another mammal with a wound, preferably to or within the vicinity of the wound to enhance healing of the wound. Alternatively, cells obtained from healer mice can be used to treat a wound in a mammal. Preferred cells include macrophages, stem cells, fetal liver cells, peripheral blood leukocytes, and bone marrow cells. Extracts from these cells can be prepared using standard methodologies and used for wound treatment. The cells or cellular extracts can be placed directly at the site of the wound to promote its healing.

[0091] In another embodiment, protein products of wound healing genes whose expression is increased after wounding in healer mice can be applied directly to the area of the wound. Protein products of wound healing genes can be used in a pharmaceutically acceptable composition and can be applied topically, as is well known in the art and described below.

[0092] The lowered capacity for wound healing which occurs in aged mammals, including humans, can be enhanced by suppressing T cell function, for example using an antibody which specifically binds to a T cell receptor (TCR) or, in experimental mammals, by genetically eliminating functional T cell receptors. Anti-TCR antibodies are available in the art or can be prepared using established methodologies. Optionally, a polynucleotide encoding a single chain anti-TCR antibody can be used. Anti-TCR antibodies can be administered to mammals, including humans, to reduce levels of functional TCRs. Sub-populations of TCRs can also be targeted.

[0093] Wounds which can be treated using methods of the invention include, but are not limited to, cuts, stretches, tears, pulls, abrasions, burns, bone breaks, crushes, scrapes, contusions, bruises, and the like. Particularly, peripheral or central nerve injuries, such as crushed or severed nerves, including the spinal cord, can be treated. Methods and compositions of the invention can be used to treat and thus enhance healing of a wound by promoting processes such as angiogenesis, chondrogenesis, return of hair follicles and/or sebaceous glands, reepithelialization, rapid connective tissue proliferation, deposition of organized extracellular matrix, and restoration of normal tissue architecture and function. Surgical adhesions can be prevented by prophylactic treatment of surgical incisions using compositions and methods of the invention. These methods and compositions are useful in any situation in which regeneration or healing of a wound without formation of scar tissue is desired.

[0094] Wound healing compositions of the invention can comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those in the art. Such carriers include, but are not limited to, large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles.

[0095] Pharmaceutically acceptable salts can also be used in wound healing compositions, for example, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as salts of organic acids such as acetates, proprionates, malonates, or benzoates. Wound healing compositions can also contain liquids, such as water, saline, glycerol, and ethanol, as well as substances such as wetting agents, emulsifying agents, or pH buffering agents. Liposomes, such as those described in U.S. Pat. No. 5,422,120, WO 95/13796, WO 91/14445, or EP 524,968 B1, can also be used as a carrier for a wound healing composition.

[0096] Administration of wound healing compositions of the invention can include local or systemic administration, including injection, oral administration, particle gun, or catheterized administration, and topical administration. For treatment of wounds on the surface of the body, a wound healing composition is typically prepared in a topical form, either as a liquid solution, suspension, gel, or cream. However, solid forms suitable for solution or suspension in liquid vehicles prior to injection can also be prepared, for local treatment of internal wounds. Both the dose of a particular wound healing composition and the means of administering the composition can be determined based on specific qualities of the wound healing composition, the condition, age, and weight of the patient, the type and extent of the wound being treated, and other relevant factors.

[0097] The above disclosure generally describes the present invention. All references cited in this disclosure are expressly incorporated herein by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

MATERIALS AND METHODS

[0098] The following materials and methods were used in the examples described below.

[0099] Mice. The MRL/MpJ-Fas1Pr (hereafter referred to as MRL/1pr) mice were obtained from the Jackson Laboratory (Bar Harbor, Me.). C57BL/6 mice were acquired from the Taconic Laboratory (Germantown, N.Y.). Mice were bred and maintained under standard conditions at The Wistar Institute (Philadelphia, Pa.).

[0100] F1, F2 and MRL/1pr backcross populations were generated to conduct the genetic studies. The female parent used for generating the F2 and backcross animals was MRL/1pr. In the examples below, alleles derived from the C57BL/6 parent are designated B and the MRL/1pr-derived alleles are designated S.

[0101] Phenotyping A 2.1 millimeter through-and-through hole was made in the center of the cartilagenous part of both ears of six week old mice using a metal ear punch (Fisher Scientific, Pittsburgh, cat # 01-337B). The holes were measured at the time of wounding and followed for wound closure using a grid-etched reticle (Bausch and Lomb, 7×).

[0102] Histology. Ears were removed with scissors by cutting at the base of the pinna. They were fixed overnight in 10% buffered formalin. To facilitate sectioning, they were held flat during fixation by inverting the lid of a processing cassette on the base and sandwiching the flattened ear by applying gentle pressure with a rubber band.

[0103] Once fixed, ears were bisected across the widest point of the hole under a dissecting microscope, using a #10 scalpel blade. The two halves were then glued together with collodion, again using the dissecting microscope to obtain perfect alignment of the cut edges and hole margins. Because the collodion would most likely dissolve in reagents used to prepare specimens for paraffin embedding, the ears were sutured together using 5.0 silk on a 1½ inch straight Keith Abdominal cutting needle with a triangular point.

[0104] Tissues were embedded in paraffin and sectioned so that the cut edges containing the hole margins were in the plane of the section. Sections were stained with hematoxylin and eosin or with Gomori trichrome stain.

[0105] Genetic Analysis. Genomic DNA was prepared from the liver of each animal in the (MRL/1pr×C57BL/6)×(MRL/1pr×C57BL/6)F2 population. Frozen tissue was homogenized and digested overnight with 100 mg/ml proteinase K. Samples were treated with two phenol:chloroform extractions and one final chloroform extraction. Finally, genomic DNA was purified by an overnight dialysis against TE buffer.

[0106] PCR primers, purchased from Research Genetics (Huntsville, AL), were employed to perform a genome wide scan of the mouse. Amplification was conducted using Boehringer Mannheim reagents with the following concentrations: 1×PCR buffer, 0.375 mM dNTPs, 0.5 U/μls of Taq polymerase, 0.165 μM of each primer, and 160 ng/20 μls of genomic DNA. Cycling conditions include a 1 min at 95 ° C. denaturing, 35 to 50 cycles of 1 min at 94 ° C., 1 min 30 sec at 55 ° C., 2 min 10 sec at 72 ° C., and a 6 min final extension at 72° C. PCR products were resolved using 3% Metaphor agarose (FMC) and were visualized through ethidium bromide staining. This method was followed for the majority of polymorphic markers. In the case of small base pair differences, PCR amplification was carried out using 32P-ATP labeled forward primers as described (38). Radiolabelled PCR products were then fractionated by size on 6% denaturing polyacrylamide gels.

[0107] Statistics. Genotype data was organized and analyzed through the use of Map Manager QT (39). For quantitative trait analysis, critical threshold values for significance of linkage were determined by the permutation test, based on a regression model developed by Churchill and Doerge (40, 41). The values for the additive model of inheritance were calculated in terms of a likelihood ratio statistic (LRS).

[0108] The threshold in the F2 under assumptions of the additive model for suggestive linkage is LRS≧3.3 and for significant linkage is LRS≦10.7. The dominant, free and recessive models were also tested and did not show a significant difference (i. e., they were less than 18-fold different) in resultant p values. The additive regression model was used because it is the simplest model and because it is consistent with the mode of inheritance of the quantitative trait loci (QTL) determined in this study. It should also be noted that the use of the additive regression model does not assume the pattern of inheritance to be strictly additive and at present the degree of additivity and dominance has not been determined. The threshold values in the backcross are 3.7 and 11.8, respectively. Loci were named as healing quantitative QTL if they independently attained significance in either cross or a suggestive level of significance in one cross, confirmed in the other (p <0.05). Microsatellite markers were evaluated individually for linkage to the healing phenotype, based on the threshold values. In addition, a mean healing score for markers closely linked to each healing QTL was calculated independently of other loci using ANOVA, using a Bonferroni/Dunn post-hoc test for making the three possible pairwise comparisons in the F2, resulting in single-locus genotypic values (Table 3) (45).

EXAMPLE 1

[0109] Kinetics and Gross Aspects of the Wound Healing Phenotype

[0110] C57BL/6 and MRL mice were ear punched using a standard metal ear punch to create a well circumscribed circular surgical wound of about 2 mm in diameter at a site at which the thickness of the ear is considerably less than a millimeter. The animals used initially were within the 8-12 week young adult age range so that early developmental considerations would not be an issue. As can be seen in FIG. 1, by day 15 maximal closure was achieved in the C57BL/6 with a 30% reduction in the original hole diameter, which remains stable. In contrast, the MRL achieves an 85% reduction in hole diameter by day 15 with complete closure by day 25. Re-examination of the ears on day 81 showed no further changes.

[0111] In FIG. 2, the closed MRL wound is evident and it is difficult to identify the original site of the hole since there is no fibrosis or scarring.

EXAMPLE 2

[0112] Histological Aspects of the Wound Healing Phenotype

[0113] Histologic sections of healing ear punch holes were examined during the first two days after injury to determine if there was a defect in the ability of their epithelium to migrate across the cut edge of the dermis and cartilage, thereby allowing uninhibited connective tissue proliferation (FIG. 3). However, not only did epithelium promptly migrate across the MRL wounds, but this change occurred one day earlier for MRL mice (day 2) than for C57BL/6 mice (day 3). Indeed, for MRL mice epithelium completely covered virtually all wounds examined after day 1. Epithelium covered all C57BL/6 wounds examined after and including day 3, except for one wound from day 5 (FIG. 4A) which showed continued presence of eschar with migrating epithelium failing to bridge the cut edge.

[0114] As ears were prepared for histology, two grossly observable differences were noted between C57BL/6 and MRL. First, for all time points, the tissue surrounding the wounds in the MRL ears was severely hyperemic when compared to that of the C57BL/6 wounds. Second, starting on day 4, and continuing on each succeeding day, a prominent annular swelling was observed around the MRL wounds that was absent for C57BL/6 wounds.

[0115] Consistent with the grossly observable differences between the wounds, histological examination at each timepoint (5 days, FIG. 4A; 10 days, FIG. 4B; 20 days, FIG. 4C) showed a marked difference in the degree of angiogenesis, cell proliferation, connective tissue matrix formation, fibroblast migration, and ECM deposition which occurred in the two strains. Also, the presence of hair follicles with accompanying sebaceous glands within the healing wounds was noted for both MRL and C57BL/6 wounds but appeared more prominent and numerous in MRL than in C57BL/6 wounds.

[0116] At all of these time points, C57BL/6 wounds have shown limited progression beyond the cut cartilage margins and have a distinct paucity of epidermal hair follicles and sebaceous glands. In contrast, the MRL wounds show marked progress towards full closure due to extensive dermal proliferation and are well supplied with hair follicles and sebaceous glands in the new growth zone. ECM is laid down so as to preserve normal architecture, underlying connective tissue is hyperplastic, and the epidermis is rich and thick. The ear cartilage layer has not significantly extended into the wound site beyond the initial cut margin.

[0117] C57BL/6 and MRL ears are shown on day 81 after wounding in FIG. 5. Numerous ingrowths of cartilage can be seen in the MRL ear that are absent from the C57BL/6 ear. The cartilage ingrowths are surrounded by numerous adipocytes which normally make up the minor subcutaneous or hypodermal layer connecting ear cartilage to dermis. It is not clear why fat cells have come to be such a prominent cell type by this time point.

EXAMPLE 3

[0118] The Pattern of Inheritance of the Wound Healing Trait is Quantitative

[0119] Our initial findings on the hereditary nature of the wound healing trait can be seen in FIG. 6 (upper panel). In these studies, mice were ear punched at 6 weeks of age and were examined at 2 weeks and 4 weeks after ear punching. The 4 week ear hole size of the MRL mice ranged from 0 to 0.4 mm, while the ear hole size of the C57BL/6 mice ranged from 1.2 to 1.6 mm. These two healing phenotypes were non-overlapping. Fifteen F, mice bred from MRL×C57BL/6 had ear holes intermediate between the two parents (ranging from 0.4 to 1.1 mm).

[0120] In an initial experiment, two backcross populations were created by using (MRL female×C57BL/6 male) F1 females and mating them to the parental males (FIG. 6, lower panel). The backcross population to MRL displayed a curve skewed to MRL-type healing. In the backcross population to C57BL/6, the progeny showed a curve with its mean displaced to C57BL/6-type (i.e. poor) healing. The healing thus appears to be a quantitative trait.

EXAMPLE 4

[0121] The Pattern of Inheritance of the Wound Healing Trait

[0122] All MRL mice quickly and effectively close the wounds in their ears; C57BL/6 (B6) mice are unable to completely close their wounds (36). The F1 has an intermediate phenotype, with considerable variability (FIG. 7). Like the F1, the (MRL/1pr×B6)F2 population demonstrates a bell-shaped curve of healing diameters (FIG. 7). The backcross (BC1) population to MRL/1pr ((MRL/1pr×B6)F1×MRL/1pr ) displays a curve skewed to MRL/1pr-type healing, whereas in the backcross population to B6 [(MRL/1pr×B6)F1×B6], the progeny show a mean displaced to B6-type (i.e. poor) healing (36).

[0123] The healing profiles of each of the populations used in this study are given in Table 1. The distribution of the variance in each of these populations compared to those of the parental and F1 mice were used to give a rough estimate of the number of unlinked genes that contribute to this quantitative trait (42, 43). From this calculation, it is likely that at minimum three to four unlinked loci (QTLs) have an impact on the healing trait in this strain combination.

EXAMPLE 5

[0124] Mapping of SSLP Markers and Significant Threshold Values

[0125] A total of 436 SSLP markers were tested for potential polymorphisms between the two strains of mice. Ninety two markers detected allelic variants in the parental strains and therefore were used for genotyping of the segregating populations. Markers were chosen based on their location in the genome, in an attempt to make a linkage map with an even spacing of 20 centimorgans between markers to generate a complete genome-wide scan (44). In regions where linkage to the healing trait was detected, the density of markers was increased to obtain a more accurate genetic dissection in the area of interest. Overall, genomic coverage reached 97.7 percent across the nineteen autosomes. Surprisingly, despite the distant genetic relationship between these two inbred strains (13, 37), no polymorphisms were found on the X chromosome (0/18 primers tested, data not shown).

[0126] The 92 polymorphic microsatellite markers were then used to map the wound healing/regeneration trait in 101 mice from the (MRL/1pr×C57BL/6)F2 intercross. For assessment of the probability of genetic linkage, critical values were calculated from this database using the permutation test (40; see Materials and Methods). The order of all markers in this linkage analysis was consistent with the order predicted by the available genomic maps (Whitehead Institute/MIT, and Mouse Genome Database, The Jackson Laboratory, Bar Harbor, Me.: www.informaticsjax.org).

EXAMPLE 6

[0127] Mapping of Quantitative Trait Loci Linked to the Healing Phenotype in the F2 Population

[0128] Table 2 shows all of the microsatellite markers that were positive for linkage to the healing phenotype in two crosses and Table 3 lists the healing scores for markers associated with wound closure. Table 9 shows microsatellite markers that were positive for linkage to the healing phenotype analyzed separately for male and female mice.

[0129] In the F2 cross, QTLs that contribute to the healing phenotype and are derived from MRL/1pr exist in three primary support intervals. Two of these QTLs are located on individual sites on chromosome 13, and are designated heal2 and heal3. These QTLs are located as follows (with their corresponding microsatellite marker): heal2, on proximal chromosome 13, near D13Mit115 (p=0.0019) and heal3, at a more distal location near D13Mit129 (p=0.0010). One of the two QTLs on chromosome 13 (heal3) has achieved significant likelihood of linkage to the healing trait while the other (heal2) is suggestive, though confirmed in a second cross (see below).

[0130] Multiple markers near these loci show a suggestive level of significance, including for heal2: D13Mit135 and D13Mit116 and for heal3: D13Mit53, D13Mit151, D13Mit144, and D13Mit107 (Table 2). D13Nds1 and D13Mit119 both achieved highly suggestive LRS values but the assignment of a QTL in this region is provisional at the present time because the 95% confidence intervals for these markers and the two flanking QTLs overlap (not shown). Nevertheless, there are distinct breaks between these QTLs in the level of significance for their linkage to healing with no deviation from the predicted order of these markers. A second region that contains a QTL with significant linkage to the healing phenotype was detected on chromosome 15, in the region of marker D15Mit244 (p=0.0011). Other microsatellite markers mapping to this location which meet the criteria for suggestive linkage to wound healing include D15Mit 172 and D15Mit 14. We have designated this QTL heal4.

[0131] In addition to the QTL on chromosome 13 and chromosome 15, which have MRL/1pr-derived healing alleles, a B6-derived healing QTL was mapped to chromosome eight, near the marker D8Mit211, with a significant LRS value (10.7, p=0.0011). Other markers in this location which showed linkage were D8Mit132, D8Mit 166, and D8Mit249. This locus was the first QTL identified and was designated heal1.

[0132] The contribution of each heal locus to the process of wound closure, as expressed by the single-locus genotypic values (45) (Table 3), generally fit an additive mode of inheritance, with the heterozygote healing score approximately halfway between the scores of the two homozygotes. One exception is the heal3 QTL, which may be recessive (i.e., heal3s/s homozygotes show significantly better wound closure than either heterozygotes or heal3b/b homozygotes). In addition, the heal3 QTL appears to interact with heal1 to give the most completely healed ear holes (ANOVA, p=0.017). The average residual wound in heal1b/b homozygotes is 0.73+0.27; however, in animals that are both heal1b/b and heal3s/s, residual wound size is 0.53+0.30 (FIG. 2). Conversely, in mice homozygous for heal1s/s but also homozygous for heal3b/b, the residual wound size is 1.2+0.22. Other pairs of heal QTLs also show these largely additive interactions, but do not attain statistical significance.

EXAMPLE 7

[0133] Mapping of Quantitative Trait Loci Associated with the Healing Phenotype in the Backcross

[0134] To confirm the linkage assignments seen in the F2, we conducted a small backcross study (42 mice), using (MRL/1pr×B6) F1 females and MRL/1pr males as parents. The F1 between MRL/1pr and B6 has an intermediate wound closure phenotype, and all progeny in this cross were expected to show intermediate to good healing. In fact, this was largely the case, although several mice in the backcross had poor wound healing. An analysis of this cross showed linkage to healing at locations that coincided with the supported intervals of association seen in the F2 for both of the two QTLs on chromosome 13 (heal2 and heal3). These QTLs were near markers D13Mit115 (LRS value=5.0, p=0.0261) and D13Mit129 (LRS value=8.3, p=0.0040), respectively (Table 2). In addition, linkage to the healing phenotype was also detected on chromosome 12 (heal5) at marker D12Mit132 with a LRS value of 10.9 (p=0.0009) and at the closely-linked marker, D12Mit233 (LRS=9.4, p=0.0022). This linkage was supported by suggestive linkage in the F2. The single locus genotypic value for residual wound diameter for the heal5 (D12Mit132) QTL is also given in Table 3. Finally, a locus showing a highly suggestive LRS value of 10.2 (p=0.0014) was found on chromosome 7 near marker D7Mit220.

EXAMPLE 8

[0135] Differential Gene Expression in Healer and Non-Healer Mice

[0136] Assays were carried out to analyze differential gene expression in healer versus non healer mice at different times during the healing process after ear punch.

[0137] SAGE analysis. mRNA transcripts were identified and their levels quantitated using the SAGE technique, as described in U.S. Pat. 5,695,937. In order to use SAGE for transcript identification and quantitation, messenger RNA (mRNA) was first prepared from the desired cell or tissue sample. Complementary DNA (cDNA) was then synthesized from the mRNA using standard techniques. The entire population of cDNA molecules was treated to create a single unique “tag” from each cDNA. These tags are listed in Tables 12 (C57BL/6) and 13 (MRL).

[0138] The sequence of the tags serves to identify each transcript. The number of times each tag occurs measures the number of copies of the mRNA originally present in the biological sample. Tags can then be identified and quantitated. Gene expression data obtained from SAGE analysis of each tissue was stored in a database to facilitate multiple comparisons with gene expression in other tissues.

[0139] Microarray analysis. Gene expression in wound tissue of healer and non healer mice and their progeny was analyzed using the Atlas Mouse cDNA Expression Array (Clontech). This array includes 588 genes that play key roles in a variety of biological processes. cDNA was synthesized from healing wound tissue from healer and non healer mice, labeled with 32P, and hybridized separately to the arrays according to the protocol provided. After a high-stringency wash step and autoradiography, expression profiles were obtained.

[0140] RT-PCR and Differential Display. The presence of known gene products in healing wound tissue was analyzed using RT-PCR and Differential Display analysis. cDNA was synthesized from RNA using reverse transcriptase. The cDNA was amplified using specific primers and displayed as fragments by gel electrophoresis for comparison. Quantitation was carried out using titrations of input material, and then samples were compared. This method is valuable for assessing the presence of known gene products and is relatively quantitative.

[0141] Expression of candidate genes identified in the genome screen described above, were separated into the following groups. Group I comprises genes which may be directly involved in wound healing based on their mapping to a chromosomal locus identified in the genome screen. Group IA comprises genes in loci whose correlation with wound healing are statistically suggestive. Group IB comprises genes in loci whose correlation with wound healing are statistically significant. Group II comprises genes which are regulated by products of the mapped genes in Group I.

[0142] The results of these assays are given in Tables 5-8. Differential expression of several candidate gene products were confirmed in two assays: MSX-2 or HOX8 (chromosome 13) and RARG (chromosome 15) were identified by both RT-PCR and microarray analyses at early time points. The gene encoding epidermal keratin (on chromosome 15) was identified by microarray at all time points and by SAGE analysis. Expression of RARG and epidermal keratin could be related, because retinoic acid (RA) causes growth of epidermal cells via the RA receptors in skin (i.e., RARG). Epidermal keratin would then be upregulated.

EXAMPLE 9

[0143] Quantitative Trait Loci Associated with Healing

[0144] The Mouse Genome Database and associated literature were searched for potential candidates near the heal QTL (Table 4). The first locus, heal 1, located on chromosome 8, is derived from C57BL/6 and is one of the strongest QTL of the five (p=0.0011), In the absence of contributing genes from MRL, C57BL/6 mice clearly cannot accomplish complete wound closure with heal1 alone. It has been shown that alleles that contribute to a trait from a parental strain that does not display that trait are not uncommon (46). Thus, it is not surprising that heal1 shows a strong additive effect with MRL loci in the F2 (see FIG. 8). Candidate genes for heal1 (Table 4) in the strongest supported interval include the guanine nucleotide binding protein alpha 0, Gnao, an alpha subunit of a heterotrimeric G-protein which interacts with an activated G protein coupled receptor (Gp-cr), preceding downstream signaling (47). It is interesting to speculate that the basis of the additive interaction of heal1 with heal3 is an interaction between the gene products encoded by Gnao and the Gp-cr 18 found in the heal3 interval.

[0145] Though the method used for determining QTL cannot separate multiple loci in the same linkage group, we have observed highly suggestive LRS values for two regions of chromosome 13 in addition to the two QTLs identified (Table 2). That these may be unique QTLs is supported by the fact that they are separable from each other in phenotype congenics that have been generated (data not shown). One of these regions is located on chromosome 13, near marker D13nds1. Msx2 (also known as Hox8) is found in this interval and is expressed in regenerating amphibian tissue (48) as well as regrowing fingertips in neonatal mice (49). In this regard, we have evidence that Msx2 expression is different in healing ear tissue between MRL and B6 mice (Samulewicz et al, manuscript in preparation). This difference could be due to a polymorphism in the Msx2 gene itself, or to the indirect effect of an FGF signaling difference (50) mediated through the FGF receptor, FGFR4 (51), which is also encoded by a candidate gene located in this interval.

[0146] Heal4 is found on chromosome 15 near marker D15Mit244. The chromosome 15 QTL is strongly associated with the wound closure trait (p=0.0011) and is located in an area rich in candidate genes, including the gene encoding retinoic acid receptor gamma (Rarg), members of the keratin family which influence differentiation in the epidermis, as well as developmental genes known as homeobox and wnt genes. The retinoic acid pathway is known for its role in regeneration in amphibians (32, 34, and 52). Furthermore, the gamma subtype of the RAR displays preferential expression over the alpha and beta subtypes in skin and cartilage tissues (53), which is the site where the MRL/1pr healing trait is evaluated in the present study.

[0147] Finally, this set of genes does not include the fas gene, H-2, or any other gene known to play a role in the autoimmune profile of MRL/1pr mice. Several lines of evidence support this. First, our previous findings showed that the MRL/MpJ mice heal similarly to MRL/MpJ-Fas1Pr mice (36). Secondly, intervals containing wound-healing genes in our crosses showed no overlap with those from another report on the genetic analysis of MRL/1pr autoimmune phenotypes (17). Third, we tested the lymph node cell number, a parameter associated with lymphoproliferation, of each of 101 F2 mice in a regression comparison with their healing phenotype, and no association was found with the healing trait (r2=0.0002, p=0.89) (Blankenhorn, et al., in preparation).

[0148] The MRL/1pr mouse strain was originally selected for its large size (13, 37); it was subsequently found to have a major defect in immune regulation, due to a retrotransposon insertion into the second intron of the fas gene (16, 54). This mouse exhibits immunological defects closely mimicking those of the human disease, systemic lupus erythematosus (SLE) and other lymphoproliferative disorders (14, 15). In the present study, however, none of the five healing QTLs nor the highly suggestive regions identified displays linkage to the fas gene or other genes proposed thus far to control the other autoimmune phenotypes seen in this strain of mouse.

EXAMPLE 10

[0149] Optic Nerve Regeneration in MRL Mice

[0150] Healer (MRL/+) and non-healer (C57B1/6) mice were anesthetized and the optic nerve was cut using a micro-dissecting spring scissors from behind the left eye socket. The optic nerve was visually inspected to identify a cut end. The right eye was not touched. The mice were examined after 1.5 months.

[0151] Tissue from both the control right eye and the left eye where the optic nerve had been transected was removed, fixed in formalin, and embedded in paraffin. Serial sections were made and stained with hematoxylin and eosin. Several tissue sections were destained and restained with Bodian's silver stain to visualize axons.

[0152] In the all three non-healer mice the left eye had completely atrophied and had sunken into the eye socket while the control, right eye appeared normal (FIG. 9B). There was no evidence of eye-specific tissue in the left socket, although lacrimal gland tissue was present. The optic nerve near the eye and the chiasm had disappeared. Thus, there was no evidence of the presence of any part of the left eye or the associated optic nerve remaining in these animals.

[0153] In contrast, in all four healer mice the left eye had either only slightly sunken or was of normal size when compared to the right (control, non-treated) eye which was normal (FIG. 9A). The optic nerve could be found in both eyes of all four healer mice and the chiasm appeared normal. The right (control, non-treated) optic nerve appeared normal in each case.

[0154] Histologic sections of eye-specific tissue from both healer and non-healer mice were examined 1.5 months after the optic nerve of each mouse's left eye had been surgically transected. In the healer mice, longitudinal serial sections of the right (control) eye tissue exhibited a normal, uncut optic nerve (FIG. 10). However, histologic sections of tissue from the left eye of healer mice demonstrated, in the first and last sections, a cut optic nerve (FIG. 11). More importantly, the middle histologic sections exhibited an increasing neural connection between the cut regions of the optic nerve. FIG. 11 shows an example of a restored optic nerve region as being thinner and irregular when compared with the uncut optic nerve of the (control, non-treated) right eye shown in FIG. 10.

[0155] Further, there appeared to be connective tissue and infiltrating macrophages filled with melanin as well as a proliferation of glial cells, especially oligodendrocytes, in the left eye-specific tissue of healer mice. Additionally, a blood vessel can be seen running along side the restored optic nerve in FIG. 11. This observation is important because cross-sections of uncut normal and healer optic nerves have blood vessels which run along side and are embedded into the optic nerve. These blood vessels would have been unavoidably cut upon transection of the optic nerve. Thus, it appears that the healer mice demonstrated regrowth of the blood vessels running along the restored optic nerve in addition to regeneration of the optic nerve itself.

[0156] Several sections were then destained and restained to visualize axons with Bodian's silver stain. As can be seen in FIG. 12A, the healer uncut (right) eye has bundles of nerves woven through the optic nerve. On the other hand, the cut (left) healer optic nerve (shown in FIG. 12B) has a left optic nerve which appears to be generally depleted of nerve fibers. On the side of the healed optic nerve nearest to the eye, nerve fibers can be seen growing towards the brain. These fibers can be seen leaving a nerve cell body and having directionality (FIG. 12B). Near the newly grown nerve fibers are an abundance of oligodendrocytes.

[0157] Thus, healer MRL mice can regenerate nerve tissue. More specifically, all four MRL mice in which the left optic nerve was transected exhibited regrowth of the optic nerve within 1.5 months after transection. In these mice, the left optic nerve has clearly been cut but a neural connection was reestablished, with marked cellular proliferation including infiltrating macrophages filled with melanin and oligodendrocytes. Further, vascular connections had also been reestablished in the left healer eye as demonstrated by the presence of a blood vessel running along the side of the restored optic nerve. By comparison, the non-healer mice had no eye-specific tissue in the left eye socket and no nerve regeneration was detected.

[0158] Nerves which have been examined using the above-described procedures are the peripheral nerve, including the sciatic nerve, and central nervous system nerves including the optic nerve, brain stem and spinal cord.

EXAMPLE 11

[0159] Restoration of Function in MRL Mice Following Sciatic Nerve Crush

[0160] Three strains of mice, C57BL/6, MRL and A/J, were examined after sciatic nerve crush. The percent of sensory function index (SFI), which is related to sciatic nerve function, is the comparison of the gait of the mouse having a normal left and a cut right sciatic nerve. To measure the SFI, the footpads of the animals were inked, and the animals were allowed to walk on a paper pad in a housing which forces them to walk forward. The pattern of ink deposition is directly related to the SFI, which was then calculated for each mouse.

[0161] The results of these experiments are shown in FIG. 13. Significant recovery of sciatic nerve function was observed in MRL mice (50% of 2/3 mice) at day 30. In contrast, C57BL/6 and A/J mice exhibited an average negative SFI value, indicating that the sciatic nerves in these animals did not recover.

EXAMPLE 12

[0162] Involvement of T Cells in Healing in Aged Healer Mice

[0163] Several facts indicated that T cells might play a role in wound healing in aged healer mice. First, scarless healing occurs in fetal mice until embryonic day 16, when T cells develop in the thymus. Second, in MRL/1pr mice, the number of lymphocytes increases with age. Third, aged healer mice do not heal as well as younger healer mice (FIG. 17). We therefore examined the role of T cells in the enhanced healing response of these mice in two ways.

[0164] First, we treated aged (5 month-old) healer mice with antibodies against T cell receptors and punched a 2 mm ear hole in the treated aged mice. As measured by this assay, aged mice which were treated with anti-TCR antibodies became complete healers, similar to their younger counterparts (FIG. 18).

[0165] Second, we crossed a member of the F1 generation from a cross between a healer and a non-healer mouse whose T cell receptors had been genetically eliminated, or “knocked out.” Members of the resulting F2 generation were then examined for a healer phenotype using an ear punch assay and for the presence of T cells by flow cytometry. Approximately 12% of the F2 generation had no T cells and were complete healers. (FIG. 19).

[0166] These results suggest that T cells somehow suppress the healing response in aged healer mice and that elimination of functional T cells restored the healing capacity of the mice. T cells obtained from non-healer mice can now be transferred into healer mice to determine whether the T cells, or a particular population of the T cells, have an effect on the enhanced wound healing of healer mice.

EXAMPLE 13

[0167] Adoptive Transfer of Fetal Liver Cells from Healer Mice Into X-irradiated Non-Healer Recipients Enhances Wound Healing

[0168] C57BL/6 mice were lethally irradiated. After 24 hours, each mouse received an injection of fetal MRL liver cells into the tail vein. Ear punches were performed at 2, 4, and 6 months after injection of the liver cells.

[0169] No healing was observed in the ears of mice after 2 or 4 months. After 6 months, however, ear holes of the C57BL/6 (non-healer) mice exhibited a healing response. This response was correlated with the detection of chimeric cells in the thymus and/or lymph node of the mice, as shown in FIG. 20.

[0170] Thus, it is possible to transfer the ability to heal ear holes to adult non-healer mice using adoptive transfer of fetal liver cells from a healer mouse strain.

EXAMPLE 14

[0171] Adoptive Transfer of Macrophages Obtained from Healer Mice to Non-Healer mice Recipients Enhances Wound Healing

[0172] The MRL mouse is derived from crossbreeding of LG (75%), AKR (12%), C3H (12%) and C57BL (0.3%) mice. Wild type strains of these mice were tested for their ability to heal or to partially heal 2 mm ear hole wounds. The only mouse which exhibited partial healing was the LG mouse (FIG. 14). The experiment was conducted as described herein for the MRL mouse.

[0173] Normal C57BL/6 mice were injected intraperitoneally with macrophages obtained from healer mice at the time of ear punching of the non-healer mice. The macrophages which were transferred were five day thioglycollate induced peritoneal cells obtained from an (MRL×B6)F2 T cell receptor alpha chain knockout mouse. This mouse was used because the αβ+ T cells were absent and the cells were only partially allogeneic.

[0174] Macrophages were obtained from healer mice using standard procedures, selected by adherence to plastic, and transferred to non-healer mice. Uninjected non-healer mice and non-healer mice injected with non-healer macrophages served as controls in the experiment. Ear hole closure was measured during the 30 days after wounding. The results of the experiment are shown in FIG. 15.

[0175] Healer macrophages induced the best ear closure (greater than 75%) in non-healer mice. (FIG. 21). Macrophages which were obtained from non-healer mice and which were transferred into non-healer mice were unable to confer healing on non-healer mice. These results establish that tissues and cells obtained from healer mice can be used to confer healing ability on non-healer mice.

EXAMPLE 15

[0176] Functional Recovery of Healer Mice Following Complete Transection of the Spinal Cord

[0177] A complete transection of the spinal cord at thoracic level (TH9-TH 11) was made in MRL and in C57BL/6 mice anesthetized with ketamine/xylazine (100/15 mg/kg, i.p.). A dorsal median incision was made over the lower thoracic vertebra. Retractors were placed in the wound to allow surgical manipulation. After exposing the vertebral arch and the spinous processes by retracting the medial part of the autochtone musculature, the osseous parts of one vertebral bone were removed with a milling cutter, leaving the dura mater intact. After continuous cooling of the spinal cord with ice cold isotonic saline to minimize bleeding, transection was performed with a scalpel. In some mice, a portion of the spinal cord was removed, rather than simply cut. In these mice, more of the spinal cord is exposed, by removing only the caudal part of the more cranial vertebral arch. The cranial part of the more caudal vertebral arch was also be removed to minimize vertebral instability. Two transections were performed, and the tissue between the transections was removed with a fine forceps.

[0178] Ice cold isotonic saline was then applied in pulses until no bleeding occurred. The muscles of both sides were repositioned and gently opposed by single 8-0 resorbable sutures. The skin was closed in the usual manner with single sutures using 8-0 Dexon (Polyglycolic Acid).

[0179] Animals were weighed daily to ensure proper water and nutritional intake. Food and water was made available at ground level through a special device. In the first postoperative days, each mouse was watched carefully for its ability to eat and drink, unless it was fed manually. The bladder was emptied 3 times a day by applying gentle pressure to the abdomen. The mice were also carefully watched for potential injury and self mutilation due to loss of innervation of the hind limbs.

[0180] After 2 days of postoperative recovery, the mice were examined for loss of lower limb innervation. Both strains showed no innervation of the hind limbs, which were dragged behind. After 2 weeks, neither strain of mice showed signs of innervation of the hind limbs. Between seven and nine weeks, however, MRL mice regained partial proximal innervation of the tail and lower limbs, exhibiting the ability to flex and then extend their hind legs. C57BL/6 mice continued to show no movement of the hind limbs or tail and to show degeneration of the limb musculature and fixed flexion of the joints. In contrast, fixed flexion of the joints of the MRL mice never occurred, and only minor muscle degeneration was in the observed first month.

[0181] Histological examination revealed that MRL mice produced only a minor scar between the two ends of the transected spinal cord (2-5 cell layers), whereas C57BL/6 mice produced a conventional glial scar (10-15 cell layers), thereby preventing the spinal cord to reconnect on an axonal level.

[0182] The partial functional recovery in MRL mice, as well as the underlying histomorphology, suggests that regeneration and reconnection on the axonal level of the spinal cord of MRL mice can occur after complete transection of the spinal cord.

EXAMPLE 16

[0183] Differential Expression of Genes in Dendritic Cells of Healer and Non-Healer Mice

[0184] Dendritic cells (immature macrophages) were isolated from the bone marrow of adult C57BL/6 and MRL+ mice using standard procedures. Total RNA was isolated from the dendritic cells and subjected to microarray analysis, as described above in the Materials and Methods section.

[0185] Table 15 shows genes which were increased more than 50% in either MRL+ or C57BL/6 mice. The gene names and array locations are from the Clontech web site (http://www.clontech.com/clontech/JAN98UPD/Atlaslist.html).

EXAMPLE 17

[0186] An in Vitro Assay of Wound Healing

[0187] A hole was punched in the ear of a healer and a non-healer mouse. Two days later, an explant of the ear tissue, including the punched hole, was excised, embedded in a collagen gel, and maintained in vitro.

[0188] FIG. 22 shows explants of healer (FIGS. 22A, B) and non-healer (FIGS. 22C, D) ear punch explants in vitro. FIG. 23 shows cells migrating away from the explant of the healer ear punch, possibly in response to factors which are produced by the wounded ear.

EXAMPLE 18

[0189] Adoptive Transfer of Bone Marrow-Derived Dendritic Cells from Healer Mice into Non-Healer Immunodeficient Mice Enhances Healing

[0190] Dendritic cells were isolated from healer (MRL+) and non-healer (C57BL/6) mice as described in Example 16. C57BL/6 Rag−/− mice, which are immunodeficient and unable to reject the dendritic cells, were ear-punched to make a 2 mm hole and immediately injected intraperitoneally with dendritic cells of either MRL+ or C57BL/6 mice. Ear hole closure was measured at 0, 2, 5, 10, 18, 24, and 27 days after wounding. The results of this experiment are shown in FIG. 23.

[0191] Healer dendritic cells induced the best ear closure (approximately 90%) in the non-healer mice, demonstrating that the healer dendritic cells can be used to transfer enhanced healing ability to non-healer mice.

EXAMPLE 19

[0192] Segregation of Quantitative Trait Loci in Phenotype Congenic Mice

[0193] Congenic mice were generated by six successive back-crossings of the F1 generation of a healer (MRL)×non-healer (C57BL/6) cross with its non-healer parent strain. Segregation of quantitative trait loci was examined in healer phenotype congenic mice (see Examples 5-8, above). Each of the 17 phenotype congenic mice examined healed a 2 mm ear hole from at least 75% to 100% 30 days after punching.

[0194] Table 16 shows that only certain markers segregate with the healer phenotype in these phenotype congenic mice. These mice are therefore useful for dissecting out the minimum number of chromosomal loci and genes involved in enhanced wound healing.

TABLE 1
Residual wound size
Parental strains and hybrid	Backcross and intercross progeny
C57BL/6	1.10 ± 0.27	F1 × MRL/lpr	0.35 ± 0.27
MRL/lpr	0.04 ± 0.06	F1 × B6	0.95 ± 0.25
(MRL × B6)F1	0.73 ± 0.22	(MRL × B6)F2	0.83 ± 0.28
Numbers are the diameter of holes in mm ± standard deviation (SD) on day 28-30. F1 = (MRL × C57BL/6)F1 hybrid.

[0195]

TABLE 2
Location of heal QTL as determined in the
intercross (F2) and the backcross (BC1) progeny.
MGD		F2	F2	BC1	BC1
cM	Primers	LRS1—	p value	LRS2—	p value	QTL
71.5	D1Mit288	6.1	0.0130		ns
105	D2Mit148		nd	4.8	0.0279
55.6	D4Nds2 4.2	4.2	0.0400		ns
77.5	D4Mit127	5.5	0.0190		ns
52.4	D7Mit220		ns	10.2*	0.0014
21	D8Mit191		ns	6.4	0.0115
33	D8Mit132	5.5	0.0188		ns
37	D8Mit249	7.3	0.0069		ns
49	D8Mit211	10.7	0.0011		ns	heal1*
56	D8Mit166	7.3	0.0068		nd
34	D12Mit4		ns	7.1	0.0077
52	D12Mit233	6.1	0.0137	9.4	0.0022
52	D12Mit132		nd	10.9	0.0009	heal5*#
9	D13Mit135	9.4	0.0022	4.8	0.0290
11	D13Mit115	9.7	0.0019	5.0	0.0261	heal2*#
13	D13Mit116	8.7	0.0030	5.1	0.0230
30	D13Mit245	7.5	0.0335		nd
32	D13Nds1	10.2*	0.0014		ns
44	D13Mit126	7.4	0.0065		ns
44	D13Mit191	10.2*	0.0014		ns
47	D13Mit29	6.5	0.0101		nd
48	D13Mit107	7.4	0.0064		ns
49	D13Mit144	6.9	0.0088		nd
60	D13Mit129	10.8	0.0010	8.3	0.0040	heal3*#
62	D13Mit53	10.5	0.0012	7.1	0.0077
71	D13Mit151	8.2	0.0042	4.6	0.0318
54.5	D15Mit171	6.6	0.0104		nd
55.6	D15Mit242	7.1	0.0079		nd
57.8	D15Mit172	7.3	0.0070		nd
56.8	D15Mit244	10.7	0.0011		nd	heal4*
56.8	Di5Mit14	8.5	0.0035		ns
Underlining indicates the LRS values that were used for assigning heal QTL.
Footnotes:
1, Threshold LRS for significant linkage = 10.7, and for suggestive linkage, 3.3
2, Threshold LRS for significant linkage = 11.8, and for suggestive linkage, 3.7
*, see text for discussion
# , confirmed in second cross

[0196]

TABLE 3
Single locus genotypic values for heal1 to heal5.
	D8Mit211 (heal1)	D13Mit115 (heal2)
Genotype	avg	stdev	p*	avg	stdev	p
b/b	0.73	0.27	0.0319	0.96	0.25	0.0904
b/s	0.84	0.27	0.1214	0.84	0.29	0.0567
s/s	0.95	0.28	0.0013***	0.72	0.26	0.0024***
	D13Mit129 (heal3)	D15Mit244 (heal4)
	avg	stdev	p	avg	stdev	p
b/b	0.96	0.28	0.2156	0.95	0.19	0.0485
b/s	0.84	0.22	0.0141**	0.86	0.30	0.0677
s/s	0.74	0.34	0.0022***	0.70	0.27	0.0013***
	D12Mit132 (heal5)
	avg	stdev	p
b/s	0.51	0.40	0.0005***
s/s	0.15	0.32
Averages and standard deviations for wound diameters at day 30 are given for mice sorted by the genotype of markers near each healing QTL. *, p values in the F2 are listed vertically for b/b vs. b/s, s/s vs. b/s, or b/b vs. s/s; in the backcross, p values are for the heterozygote b/s vs. the homozygote s/s. Genotype values are significant at α = 0.05 (**) or α= 0.01 (***) in post-hoc analyses.

[0197]

TABLE 4
Candidate genes in genomic intervals containing QTLs
OTL	MGD cM	Candidate genes in interval
heal1	33	Comp, cartilage oligomeric matrix protein
	39	pdw, pwportional dwarf
	42	Os, oligosyndactylism
	46	Gna0
	51.5 to 67	Cadherin family
heal2	7	Nid, nidogen
	8	Gli3, GLI-Kruppel family member GLI3
	10	Amph, amphiphysin
	10	Inhba, inhibin beta-A
	10	Rasl1, Ras-like, family 1
heal3	32	Msx2, hox8
	32.5	Fgfr4, fibroblast growth factor receptor
	33	mes, mesenchymal dysplasia
	36	Tgfbi, transforming growth factor induced
	44	Cspg2, chondroitin sulfate proteoglycan
	45	Rasa, ras p21 GTPase activating protein
	56	Gpcr18, G-protein coupled receptor 18
	62	Itga 1,2, integrin alpha 2 (Cd49b)
heal4	51.6	Pdgfec, platelet derived growth factor
	56.8	Col2a1, procollagen, type II, alpha 1
	56.8	Ela1, elastase 1
	57	Emb, embigin
	57.1	Hoxc, homeo box C cluster
	57.1	Rarg, retinoic acid receptor, gamma
	57.5	Dhh, desert hedgehog homolog
	58.7	Krt2, keratin gene complex 2
	60	Itga5, integrin alpha 5
	61.1	Itgb7, integrin beta 7
	63	Glycam1 adhesion molecule
heal5	40	Fos, FBJ osteosarcoma oncogene
	41	Tgfb3, transforming growth factor, beta
	44.6	Chx10, C elegans ceh-10 homeo domain con
	45	Pgf, placental growth factor

[0198]

TABLE 5
Differentially expressed or regulated genes identified using microarray
analysis of mRNA obtained from healing tissue on days 5 and 20 after
ear punch compared to tissue obtained on day 0.
Gene Group*	Chromosome #	Gene
IA	1	Stat 1
	1	PAI-2
	2	ABI-2
	2	Integrin alpha
	2	Basic domain transcription factor
	2	SEF-2
	4	TNFR-1
	4	SKI
	7	H-ras
	7	Cathepsin D
	8	Glutathione Reductase
	10	TIMP-3
	10	STAT6
	11	ACE
	11	Macrophage inflammatory Protein
	11	c-erb
	14	BMP-l
	14	Cathepsin B
	16	HMG
	16	ETS
	18	c-FMS
IB	2	CRAPBII (RA binding protein)
	2	CD44
	2	SKY proto-oncogene
	8	Casein kinase
	12	YY1
	12	c-AKT
	13	GTT
	13	SPI-3
	13	GKLF
	13	Cathepsin L
	13	PDGF signalling molecule
	13	thrombin receptor
	15	epidermal keratin
*Genes in Group II are listed in Tables 10 and 11. Table 10 is a list of genes which are differentially expressed on days 5 and 20 after ear punch between control mice (B6 & F2 nonhealers) and experimental mice (MRL & F2 healers). Table 11 is a list of genes which are regulated in MRL tissue from 0, 24, and 40 hrs after wounding or ear punching (see FIG. 16).

[0199]

TABLE 6
Differentially expressed or regulated genes identified using RT-PCR
analysis of mRNA from healing tissue.
	Gene Group	Chromosome #	Gene
	IB	13	MSX-2
		15	RAR-gamma

[0200]

TABLE 7
Differentially expressed genes in Groups I and II identified using
differential display analysis of mRNA from healing tissue.*
	Gene Group	Chromosome #	Gene
	IB	8	ecadherin
	II		PMG-1
			TR 2-11
			tropomyosin
	*RNA from healer and nonhealer ears on days 0, 5 and 20 after ear punching were analyzed by RT-PCR. Random primers obtained from “Gene Hunter Corp” were used to amplify bands. Since these are random primers, the products are unknown but can be sequenced. It is a useful way of examining what amplifies in one population and not another. Thus, one has to compare what is present or not in B6 and MRL for each time point and then subtract out the differences seen in day 0.

[0201]

TABLE 8
Differentially expressed genes from Groups I and II identified
using SAGE analysis of mRNA from healing tissue.
Gene Group	Chromosome #	Gene
IB	15	epidermal keratin
II		macrophage ferritin heavy subunit
		est (1758377)and see Table D

[0202]

TABLE 9
Microsatellite Markers Linked to Male and Female Healer Mice
CHROM #	MARKER	LOCATION(CM	LRS	CROSS
1	D1MIT64	21	5.1	F2-Male
1	D1MIT123	36.9	4	F2-Male
1	D1MIT288	71.5	7.5	F2
1	D1MIT356	95.8	4.3	F2-Female
2	D2MIT329	45	5.6	F2-Female
2	D2MIT37	45	6.3	F2-Female
2	D2MIT14	49	8	F2-Female
##2	D2MIT207	60	10.5	F2-Male; F2
2	D2MIT107	75.6	7.9	F2-Male
2	D2MIT223	76.7	9.3	F2-Male
2	D2MIT148	105	4.8	Backcross
3	D3MIT60	0	6.3	F2
3	D3MIT203	11.2	4.3	F2
3	D3MIT310	38.3	5.4	F2; F2-Male
##4	D4MIT149	0	13.4	F2-Male
4	D4MIT235	2	9.8	F2-Male
4	D4MIT236	12	5	F2-Male
4	D4MIT241	25	5.5	F2-Male
4	D4MIT127	78	8.8	F2-Male
5	D5MIT148	18	5.8	F2-Female
6	NONE
##7	D7MIT220	52	10.2	Backcross
7	D7MIT237	66	6.6	Backcross
8	D8MIT191	21	6.4	Backcross
#8	D8MIT211	49	9.9	B6
9	NONE
10	D10MIT42	44	3.5	F2-Female
10	D10MIT233	62	4.2	F2-Male
11	D11MIT124	61	8.1	F2-Male; F2
12	D12MIT4	34	7.1	Backcross
12	D12MIT233	52	9.4	Backcross
##12	D12MIT132	52	10.9	Backcross
13	D13MIT135	10	9.4	F2
13	D13MIT115	11	9.7	F2
13	D13MIT116	13	9	F2
13	D13MIT245	30	8.8	F2
##13	D13NDS1	32	15.9	F2
13	D13MIT126	45	6.6	F2
13	D13MIT191	45	9.4	F2
##13	D13MIT159	45	12.7	F2
13	D13MIT29	47	6.5	F2
13	D13MIT107	48	7	F2
13	D13MIT144	48	6	F2
##13	D13MIT148	59	11.9	F2
##13	D13MIT129	60	11.2	F2
13	D13MIT53	62	9.1	F2
13	D13MIT151	71	8.2	F2
14	D14MIT193	40	5	F2-Male
14	D14MIT131	58	4	F2-Male
15	D15MIT189	48.5	6.6	F2; F2-Female
15	D15MIT171	54.5	6.7	*
15	D15MIT242	55.6	6.7	*
15	D15MIT172	57.8	6.9	*
##15	D15MIT242	55.6	10.7	*
15	D15MIT14	56.8	9.3	*
15	D15MIT43	60.4	4.6	*
15	D15MIT79	66.2	7.9	*
15	D15MIT16	61.7	5.9	*
16	D16MIT122	3.85	6.2	F2
16	D16MIT32	48.2	6.6	F2
17	D17MIT68	24.5	5.7	F2
18	D18MIT123	31	4.8	F2
18	D18MIT49	49	4.1	F2
19	D19MIT59	0.5	7.2	F2-Female
The sugestive loci have an LRS value of 3.5 or greater
The significant loci have an LRS value of 10.5 or greater (except when confirmed in a second cross (##)

[0203]

TABLE 10
Wound Healing Gene Products Identified by Microarray Analysis
		Chrom. Locat.	Gene Products identified by
Day 5 Express.	Day 20 Exp.	(cM)	microarray analysis (day 5 and 20 healer and nonhealer ear holes compared to day 0)
up	up	?	Ezrfn; Villin 2; NF-2 (merlin) related filament/plasma membrane associated protein
no change	DOWN	14 (41)	Rb; pp105; Retinoblastoma susceptibility-associated protein
			(tumor suppressor gene; cell cycle regulator)
up (female)		7 (syntenic)	TSG101 tumor susceptibility protein
down(female)	down(female)	?	Tumor suppressor maspin
down(male)	down(male)	7 (28.5)	ZO-1; Tight junction protein; discs-large family member, partially homologous to a
			dig-A tumor suppressor in Drosophila
down(male)	down(male)	11 (57)	cErbA oncogene; thyroid hormone receptor
up	up	4 (44.6)	c-Jun proto-oncogene (transcription factor AP-1 component)
no change	down	?	RNA polymerase I termination factor TTF-1
up	up	15 (32)	c-myc proto-oncogene protein
down(female)	up(female)	8 (49.5)	Casein kinase II (alpha subunit)
down(male)	down(male)	17 (16.4)	Pim-1 proto-oncogene
up(female)		18 (30)	c-Fms proto-oncogene (macrophage colony stimulating factor 1 (CSF-1) receptor)
up(female)	up(female)	5 (42)	PDGFRa; platelet-derived growth factor alpha-receptor
down(male)	down(male)	4 (78.9)	Ski proto-oncogene
up		2 (67)	Sky proto-oncogene (Tyro3; Rse; Dtk)
up(female)		7 (72.2)	H-ras proto-oncogene; transforming G-protein
	down(male)	3 (48.5)	N-ras proto-oncogene: transformong G-protein
	up(male)	1 (36.1)	IGFBP-2; Insulin-like growth factor binding
			protein 2; autocrine and/or paracrine
up(female)		?	Cyclin B2 (G2/M-specific)
down	up	?	Cyclin D2 (G1/S-specific)
up(male)	down(male)	?	Cyclin G (G2/M-specific)
up	down	?	p18ink4; cdk4 and cdk6 inhibitor
down	up	?	Prothymosin alpha
up		?	HSP84; heat shock 84kD protein
up		?	HSP86; heat shock 86kD protein
up		2 (22.5)	Glucose regulated protein, 78kD; Grp78
up(male)		3 (66.2)	Golgi 4-transmembrane spanning transporter; MTP
up		13 (47)	Cf2r; coagulation factor II (thrombin) receptor
up(female)		?	Interleukin-6 receptor beta chain; membrane glycoprotein gp130
up		19(0.5)	I-kappa B alpha chain
up (male)	down(male)	1(28)	Stat1; signal transducer and activator of transcription
up(male)	down(male)	10(70)	Stat6; signal transducer and activator of transcription 6; IL-4 Stat; STA6
up		11(syntenic)	Crk adaptor protein
up	down	17(40)	Inhibitor of the RNA-activated protein kinase, 58-kDa
up		?	MAPK; MAP kinase; p38
UP	DOWN	g (36)	MAPKK1; MAP kinase kinase 3 (dual specificity) (MKK1)
up	down	2 (2)	PKC-theta
down	down	13(50)	PI-K p58,
			PDGF signaling pathway member
up(male)	down(male)	?	Rab-2 ras-related protein
up(male)	down(male)	?	14-3-3 protein eta
up		11 (29)	IRF1; interferon regulatory factor 1
UP	DOWN	?	Zyxin; LIM domain protein; alpha-actinin binding protein
up(male)	down(male)	?	BAG-1; bcl-2 binding protein with anti-cell death activity
up	up	13(8)	Glutathione peroxidase (plasma protein); selenoprotein
up		8(16)	Glutathione reductase
DOWN	DOWN	?	Glutathione S-transferase (microsomal)
down(male)		?	Glutathione S-transferase Mu 1
up	down	12(58)	c-Akt proto-oncogene; Rac-alpha; proteine kinase B (PKB)
up	down	?	FLIP-L; apoptosis inhibitor; FLICE-like inhibitory protein
up(female)	down(female)	3(70.5)	Gadd45; growth arrest and DNA-damage-inducible protein
up		?	Nm23-M2; nucleoside diphosphate kinase B; metastasis-reducing protein;
			c-myc-related transcription factor
up(male)	down(male)	?	Protein tyrosine phosphatase
up(male)	down(female)	19(23)	RIP cell death protein; Fas/APO-1 (CD95) interactor, contains death domain
UP	DOWN	13(16)	SPI3; serpin; similar to human proteinase inhibitor 6 (placental thrombin
			inhibitor) serine proteinase inhibitor
UP	DOWN	4(75.5)	Tumor necrosis factor receptor 1: TNFR-1
up(female)	UP(female)	?	PA6 stromal protein; RAG1 gene activator
up		?	MHR23B; Rad23 UV excision repair protein homologue; xeroderma pigmentosum group C
			(XPC) repair complementing protein
up		2(45)	Abiphillin-1 (abl-1) similar to HOXD3
	UP	x-14	Adipocyte differentiation-associated protein
H>>NH	H>>NH	2(91)	Basic domain/leucine zipper transcription factor
up		?	Butyrate response factor 1
NH>>H	NH>>H	?	CACCC Box- binding protein BKLF
up		?	DP-1 (DRTF-polipeptide 1) cell cycle regulatory transription factor
down(female)	up(female)	16(68.5)	Ets-2 transcription factor
down (female)	up(female)	2(7)	GATA-3 transcription factor
down(female)	up(female)	13(16)	Gut specific Kruppel-like factor GKLF
down(female)	up(female)	16(69)	HMG-14 non histone chromosomal protein
up NH>H		?	Interferon regulatory factor 2 (IRF 2)
up NH>H		?	NF-1B protein (transcription factor)
up	down	15(61.7)	Nuclear factor related to P45 NF-E2
up(male)	down(male)	9(36)	Nuclear hormone receptor ROR-ALPHA-1
up	down	6(syntenic)	Split hand/foot gene
down(female)	up(female)	2(54)	Retinoic acid binding protein II cellular (CRABP-II)
down (female)	up(female)	?	Retinoid X receptor interacting protein (RIP 15)
up	down	?	Transcription factor 1 for heat shock gene
up		?	Transcription factor CTCF (11 zinc fingers)
NH>>H	up(female)	2(94)	Transcription factor SEF2
down(female)	up(female)	?	YB1 DNA binding protein
up(female)	up(female)	12(53)	YY1 (UCRBP) transcriptional factor
NH>>H	up(female)	?	Activin type I receptor
down(f)
up(male)	down (male)	?	C-C chemokine receptor (Monocyte
			chemoattractant protein 1 receptor (MCP-1RA)
down(female)	down (female)	?	Growth factor receptor
NH>>>H	up	18(20)	Glucocorticoid receptor form A
up		6(31.5)	CD31 (Platelet, endothelial cell adhesion molecule 1)
up	up	2(56)	CD44 antigen
up		9(56)	Dystroglycan 1
up	down	?	Glutamate receptor channel subunit gamma
up		2(38)	Integrin alpha 6
UP(female)	up(female)	?	Integrin beta
UP (female)	up(female)	?	Laminin receptor 1
up(male)	UP(female)	14(32.5)	Bone morphogenetic protein 1
NH>>H up		?	Insulin-like growth factor binding protein -6 (IGFBP 6)
	up	11(2)	Insulin-like growth factor binding protein-3 (IGFBP-3)
	UP	?	Insulin-like growth factor binding protein-4 (IGFBP-4)
	UP	1(36)	Insulin-like growth factor binding protein-5 (IGFBP-5)
UP(female)	UP(female)	10(48)	Insulin-like growth factor-IA
up		11(47.6)	Macrophage Inflammatory protein
	down(male)	18(48)	Mad related protein 2 (MADR2)
up		7(11)	Neuroleukin
	UP(female)	14(20)	Placental ribonuclease inhibitor (Anglogenin)
up	down	7(6.5)	Transforming growth factor beta
up	down	7(6.5)	Transforming growth factor beta 2
up(female)		x(1.7)	Cytoskeletal epidermal keratin (14 human)
H>>>NH UP	UP	15(58.7)	Epidermal keratin (1 human)
up(male)	down(male)	9(61)	Non-muscle myosin light chain 3
up(female)		2(7)	Vimentin
up	down	11(65)	Anglotensin-converting enzyme (ACE) (clone ACE.5.)
	up	14(28.5)	Cathepsin B
	down	7(72.5)	Cathepsin D
	up	13(30)	Cathepsin L
H>>NH up(f)	down(male)	?	Cytotoxic T lymphocyte-specific serine protease CCP I gene (CTLA-1)
NH>>H	UP	14(20)	Mast cell protease (MMCP) -4
	UP(female)	?	Membrane type matrix metalloproteinase
	DOWN	1(61)	Plasminogen activator inhibitor-2
	UP	?	Serine protease inhibitor homolog J6
NH>>>H up		10(47)	TIMP-3 tissue inhibitor of metalloproteinases-3

[0204]

TABLE 11
Genes whose expression is altered in MRL mice 0 hrs.,
24 hrs., and 40 hrs. after ear punch.
Block A	Block B	Block C	Block D
1a.	APC	1a.	HSP-27	1a.	Caspase -11	1a.	abi-1
1b.	BRCA1	1b.	HSP-60	1e.	bag-1	1j.	BKLF
1e.	EB1	1c.	HSP-84	1f.	Bak	1k.	C/EBP
1f.	ezrin	1d.	HSP-86	1g.	Bax	2g.	DP-1
1i.	NF2	1f.	Osp-94	2a.	GTT trnfs.	2j.	Elf-1
1j.	p107	1j.	cyp1b1	2b.	GTT Mu-1	3m.	HMG-14
1l.	p53	2e.	Glut1	2d.	GST pi-1	3n.	Hox1.1
2a.	maspin	3d.	CXCR4	2e.	A20 znc fnger pr.	4g.	Hox 8
2d.	VHL	3f.	Prostaglandin E R	2k.	c-Akt	4m.	LKLF
2g.	c-erb	3g.	Tie-1	3a.	CHOP 10	4n.	Lbx1
2j.	TTF-1	3j.	Vegfr-2	3b.	Clusterin	5a.	Mph-1
2l.	c-myc	4h.	TANK	3f.	Fas1 R	5b.	MRE
3b.	FLI-1	4k.	Tristetraproline	4c.	Nm23-M2	5h.	NF-E2
3e.	Gli	5b.	Hck	4g.	PtPhosphatase	5m.	DSS-1
3l.	B-Raf	5f.	CamK	4h.	PS-2	5n.	Sox3
4e.	PDGFRa	5h.	Erk1	5a.	TDAG51(fas reltd)	6b.	PAX-6
4g.	SKI	5j.	Jak3	5b.	TNF 55	6f.	RXR-6
4j.	Vegfr-1	6h.	PKC-theta	5d.	TNFR-1	6g.	RIP-15
4n.	c-Src	6k.	PI3-K	6j.	MHR23B	6i.	TF-1 for HSP
5c.	H-ras	7b.	Rab-2	7b.	PCNA	7e.	SEF2
5d.	LFC
5j.	b-protachykinin	7j.	GapIII	7c.	bluelight R	7g.	SP2
5m.	IGFBP-2
6a.	cyclin A	7n.	Zyxin	7e.	Pur
6d.	cyclin B2
6h.	cyclin D3			7k.	HR6B
7b.	p58/GTA
7e.	cdk inhibit prot.			7n.	XRCC1
7j.	cdc25a
7m.	prothymosin a
Block E		Block F
1c.	BMP-R	6m.	dystroglycan	1b.	BMP-1	5i.	epid.k-18
1g.	CSA-R	6n.	glutamate R	1d.	BMP-4	5k.	epiderm keratin
2b.	FGFR-4	7a.	CD49b	1g.	Cek 5	5n.	kinesin
2e.	GMCSF-R	7c.	CD51	1h.	Cek 7	6b.	nonmuscle myos.
2l.	INFab-R	7g.	Integrin beta	1j.	EGF	6d.	vimentin
2m.	INFg-R	7i.	ICAM-1	2a.	G-CSF	6e.	unconv myosin VI
3a.	IL-1R	7j.	Laminin R 1	2i.	IGFBP-6	6g.	cathep B
3c.	1L2-R	7l.	Neuronal prot F3	2k.	IGFBP-3	6h.	cathep D
3d.	IL3R	7n.	VLA-3	2l.	IGFBP-4	6i.	cathep H
3g.	IL-7R			2m.	IGFBP-5	6j.	cathep L
3h.	IL8-R			3a.	ILGF-14	6k.	collagenase IV
3i.	Estrog R			3c.	K-FGF	6m.	CTLA-1
3j.	Androg R			3g.	MIP2	6n.	gelatinase B
3m.	Glucocort R			3h.	MADR2	7b.	MMCP-4
4a.	Insulin R			3j.	Smad 1	7c.	MTMMP
4b.	IRS-1			3k.	NGF	7e.	TPA
4h.	Serotonin R 1e-b			3m.	neuroleukin	7g.	Protease Inhib 2
4j.	Serotonin R 3			3n.	oncostatin	7i.	PAI-2
4m.	Adrenergic R beta 1			4d.	thrombomod.	7j.	Spi-2
5c.	GPCR			4g.	TGFb2	7n.	TIMP-3
5f.	GABA-A 3			5b.	IL-4
5g.	GABA-A 4			5c.	IL-6
5l.	P-selectin			5d.	IL-7
5m.	catenin alpha			5e.	cardiac myosin
6a.	CD2			5g.	CDC42 bind. prot.
6h.	CD14			5h.	epidermal keratin-14

[0205]

TABLE 12
SAGE Analysis of C57BL/6 Mice Five Days After
Wounding
SearchName = B5BANK
FileName = c:\sage\data\b5data˜1\b5bank.bag
Anchoring Enzyme = Nlalll—CATG
Tag Length = 11
DiTag Length = 24
Total Files = 56
Total Tags = 1508
Total Duplicate Dimers = 0
Tag Abundance Report
Total tags after excluding tags = 1508
Count	Percent	Tag Sequence	-Tag BaseFour Number
16	1.061	GGCTTCGGTCT	-2750136
13	.862	AGAGCGAAGTG	-563247
12	.7957	AGCAGTCCCCT	-601432
12	.7957	GTGGCTCACAA	-3054865
10	.6631	AGGCAGACAGT	-673868
9	.5968	GCTGGCCCTTC	-2598270
8	.5305	AGGTCGGGTGG	-711355
8	.5305	CGCCGCCGGCT	-1664424
7	.4641	CTGCTCAGGCT	-1995944
7	.4641	TGGGCATCCAC	-3838802
6	.3978	AAGGAAATGGG	-164075
6	.3978	ATACTGACATT	-817232
6	.3978	CCTTTGTGACT	-1571720
6	.3978	GAACATTGCAC	-2117522
6	.3978	GGGAAGGCGGC	-2755178
5	.3315	ATGACTGATAG	-925235
5	.3315	CACAAACGGTA	-1114541
5	.3315	CACCACCGTTG	-1131967
5	.3315	CAGAACCCACG	-1180999
5	.3315	CCCTGAGTCCA	-1434325
5	.3315	CCCTGGGTTCT	-1436408
5	.3315	GCCCGGGAATA	-2451981
5	.3315	GCGGCGGATGG	-2529851
5	.3315	GGAAGCCACTT	-2630944
5	.3315	TAAAGAGGCCG	-3154583
5	.3315	TATGTCAAGCT	-3388456
5	.3315	TGGGTTGTCTA	-3849949
5	.3315	TGTAGTGTAAT	-3878596
5	.3315	TTCAGTGGACC	-4009606
5	.3315	TTGGTGAAGGA	-4110377
4	.2652	AGAAACCAATA	-525581
4	.2652	AGTGAGGAAGA	-756233
4	.2652	ATAATACATAA	-799025
4	.2652	ATACTGAAGCC	-817190
4	.2652	ATTCTCCAGTG	-1013039
4	.2652	CAAACTCTCAC	-1056210
4	.2652	CAGTCACCAAC	-1233218
4	.2652	CCCACAAGGTA	-1380525
4	.2652	CCTTGCTCAAT	-1566532
4	.2652	CCTTTGAGATC	-1570958
4	.2652	CTAGTCTTTGT	-1882108
4	.2652	CTGAACATCTC	-1967326
4	.2652	GGCAAGCCCCA	-2689365
4	.2652	GGCCTGGCTTA	-2718333
4	.2652	TCCCCGTACAT	-3496724
4	.2652	TCCCTATTAAG	-3503043
4	.2652	TCTTCTCACAA	-3661073
4	.2652	TGGCCCAAATT	-3822608
3	.1989	AAGGTGGAAGA	-178697
3	.1989	ACATCATAGAT	-316196
3	.1989	AGGAAGGCGGC	-658026
3	.1989	CAAGTGGAAAA	-1096193
3	.1989	CACGCTCCCGG	-1154395
3	.1989	CAGGOCACACA	-1217605
3	.1989	CCAGAACAGAC	-1343778
3	.1989	CCCAGAGCACT	-1385032
3	.1989	CCCTAAACTGA	-1425529
3	.1989	CCTGATCTTTA	-1543677
3	.1989	CCTTTAATCCC	-1568982
3	.1989	CTCAACAGCAA	-1901713
3	.1989	CTCCTGGACAC	-1931794
3	.1989	CTGGCTTTCAG	-2006995
3	.1989	GACTTTGGAAA	-2227841
3	.1989	GAGCGTTTGG	-2256891
3	.1989	GATGACACCAG	-2327635
3	.1989	GCTGCAGTTGA	-2593529
3	.1989	GCTGCCCTCCA	-2594261
3	.1989	GTCTGCTGATG	-3008399
3	.1989	GTGGAGGCGCC	-3050086
3	.1989	GTGGGCGTGTA	-3057389
3	.1989	TAAACCTGCTA	-3151773
3	.1989	TATCCCACGCC	-3363942
3	.1989	TCGGTTTCTGC	-3587962
3	.1989	TCTCACCACCC	-3622166
3	.1989	TGACCCCGGGA	-3691945
3	.1989	TGCACAGTGCT	-3740392
3	.1989	TGGTCTGGTCC	-3858102
3	.1989	TGTAACAGGAC	-3867810
3	.1989	TTCAGGTGGTT	-4008880
3	.1989	TTGGCTGCCCA	-4103765
2	.1326	AAAACAGTGGC	-4842
2	.1326	AAAGCAGTGCT	-37608
2	.1326	AAGAGGCAAGA	-141577
2	.1326	AAGCAACAGGT	-147756
2	.1326	AAGGTCGAGCT	-177704
2	.1326	ACAGAACTCTT	-295392
2	.1326	ACCTTGGAAGG	-391691
2	.1326	ACTCTTTGTTT	-491456
2	.1326	ACTGGCTGGGC	-501674
2	.1326	ACTTATTATGC	-511802
2	.1326	AGAACCATTAA	-529649
2	.1326	AGACCCTCTCA	-546677
2	.1326	AGCAATTCAM	-593729
2	.1326	ATCAACACCGC	-853082
2	.1326	ATCCGAAAGAT	-876580
2	.1326	CACCACCACAG	-1131795
2	.1326	CACCTTGGTGC	-1146554
2	.1326	CACGGGACCAC	-1157202
2	.1326	CACTGACCTCC	-1171830
2	.1326	CATTATGGGTG	-1298095
2	.1326	CCCAATGGCCC	-1379990
2	.1326	CCCGGACTTAC	-1417714
2	.1326	CCCGTAGCCCC	-1421910
2	.1326	CCTACAGTTGA	-1512185
2	.1326	CCTCGGAAAAT	-1533956
2	.1326	CCTGTGTGAAA	-1555329
2	.1326	CGCCTGCTAGC	-1669578
2	.1326	CGCTGGTTCCA	-1698773
2	.1326	CGGTTCCACCC	-1766678
2	.1326	CTAATAAAGCC	-1847334
2	.1326	CTACCAGGATA	-1856141
2	.1326	CTGCTATCCGA	-1995609
2	.1326	CTGCTTTGTGC	-1998778
2	.1326	CTGGGCGTGTC	-2008814
2	.1326	CTGTAGGTGAT	-2018020
2	.1326	CTGTGCCCTCC	-2024822
2	.1326	CTTAAGGATCC	-2034230
2	.1326	GAATCTGAAGT	-2153996
2	.1326	GAATGCAGGGA	-2155689
2	.1326	GAGGAGAAGAA	-2263073
2	.1326	GATGCATAGTG	-2331439
2	.1326	GATGTGACCAC	-2340946
2	.1326	GATTTCTGTCT	-2357176
2	.1326	GCACCGAACAC	-2381842
2	.1326	GCATACGGCGC	-2410138
2	.1326	GCATTGCATCT	-2423096
2	.1326	GCCAAGGGTCA	-2427573
2	.1326	GCCAAGTGGAG	-2427811
2	.1326	GCCTAATGTAC	-2474930
2	.1326	GCCTCGGGGGA	-2480809
2	.1326	GCGACGCGGGC	-2496938
2	.1326	GCGGCGGGATG	-2529935
2	.1326	GCTCAGGATTC	-2574910
2	.1326	GCTGGCAGACG	-2598023
2	.1326	GCTTGCTTCCT	-2615256
2	.1326	GGAAGGTGTCT	-2632632
2	.1326	GGATTTGGCTT	-2686624
2	.1326	GGGAGCTGTGC	-2762682
2	.1326	GGGGAAATCGC	-2785498
2	.1326	GGGGCTCAGCC	-2792742
2	.1326	GGTGAGCCTGA	-2853241
2	.1326	GGTGGGACACA	-2861125
2	.1326	GTAAGCATAAA	-2892993
2	.1326	GTCTGGGGGGA	-3009193
2	.1326	GTGGTAGGCTA	-3060381
2	.1326	GTTGCTGAGAA	-3120673
2	.1326	GTTGGGGGGGG	-3123883
2	.1326	TAACTGACAAT	-3176516
2	.1326	TATACAATACA	-3346629
2	.1326	TCCACTGTGCA	-3481317
2	.1326	TCTGGACGCGG	-3645851
2	.1326	TGAAACACTGT	-3671164
2	.1326	TGACCCCGGGT	-3691948
2	.1326	TGCCTGTGATA	-3767181
2	.1326	TGGATCCTGAG	-3814883
2	.1326	TGGGCAAAGCC	-3837990
2	.1326	TGGTGACAAAA	-3858689
2	.1326	TGTGCCAAGTG	-3904559
2	.1326	TGTTCATCTTG	-3920767
2	.1326	TTCAGCTCGAG	-4007779
2	.1326	TTGCTGCAGTG	-4094255
Tags included in this report = 161
DataBase Link
Database = c:
16	1.061%	GGCTTCGGTCT	-2750136
Noted Tags = 0	Collected Tags = 0
13	.862%	AGAGCGAAGTG	-563247
Noted Tags = 1	Collected Tags = 1
GCGGAA, Class A, U93862, Mus musculus ribosomal
protein L41 mRNA, complete
12	.7957%	AGCAGTCCCCT	-601432
Noted Tags = 4	Collected Tags = 0
12	.7957%	GTGGCTCACAA	-3054865
Noted Tags = 207	Collected Tags = 56
CCATCC, Class A, AB0046, Mus musculus mRNA for Rab
33B, complete ods.
CCATCT, Class C, 129190, Mouse MHC class I H2-D
transplantation antigen gen
CCATCT, Class A, U20225, Mus musculus ad-
enylosuccinate lyase (adi) mRNA, Co
CCATCT, Class A, X931 68, M.musculus mRNA for can-
nabinoid receptor 2.
CCATCT, Class A, X56974, M.musculus mRNA for exter-
nal transcribed spacer (p
CCATCT, Class C, X52915, M.musculus gene for H-2D
(q) antigen, partial 3' c
CCATCT, Class C, V00751, Mouse gene H-2Ld coding for
a transplantation anti
CCATCT, Class C, X52916, M.musculus H-2L(q) gene
for H-2L(q) antigen. 3″ p
CCATCT, Class C, U06244, Mus musculus interferon
alphalbeta receptor (IFNAR
CCATCC, Class C, X64716, M.musculus NKR-P1 2 gene
for natural killer cell r
10	.6631%	AGGCAGACAGT	-673868
Noted Tags = 2	Collected Tags = 2
TGCTGT, Class A, X13661, Mouse mRNA for e-
longation factor 1-alpha (EF 1-alp
TGCTGT, Class A, M22432, Mus musculus protein
synthesis elongation factor T
9	.5968%	GCTGGCCCTTC	-2598270
Noted Tags = 0	Collected Tags = 0
8	.5305%	AGGTCGGGTGG	-711355
Noted Tags = 1	Collected Tags = 0
8	.5305%	CGCCGCCGGCT	-1664424
Noted Tags = 1	Collected Tags = 0
7	.4641%	CTGCTCAGGCT	-1995944
Noted Tags = 1	Collected Tags = 1
TAGGAG, Class A, M13806, Mouse keratin (epider-
mal) type I mRNA, clone pkScc
7	.4641%	TGGGCATCCAC	-3838802
Noted Tags = 0	Collected Tags = 0
6	.3978%	AAGGAAATGGG	-164075
Noted Tags = 0	Collected Tags = 0
6	.3978%	ATACTGACATT	-817232
Noted Tags = 4	Collected Tags = 0
6	.3978%	CCTTTGTGACT	-1571720
Noted Tags = 0	Collected Tags = 0
6	.3978%	GAACATTGCAC	-2117522
Noted Tags = 3	Collected Tags = 2
CACACG, Class A, X12697, Mouse p2-4 mRNA for
SPARC/osteonectin (SPARC = sec
CACACG, Class C, M20691, Mouse osteonectin (Sparc)
gene, exon 9.
6	.3978%	GGGAAGGCGGC	-2755178
Noted Tags = 2	Collected Tags = 1
ACGTCT, Class A, M88335, M.musculus mRNA sequence.
5	.3315%	ATGACTGATAG	-925235
Noted Tags = 4	Collected Tags = 0
5	.3315%	CACAAACGGTA	-1114541
Noted Tags = 0	Collected Tags = 0
5	.3315%	CACCACCGTTG	-1131967
Noted Tags = 1	Collected Tags = 1
CCTTCA, Class C, M21460, Mouse surfeit locus sur-
feit 3 protein gene, exon 6
5	.3315%	CAGAACCCACG	-1180999
Noted Tags = 2	Collected Tags = 2
ACAGTA, Class C, M76762, Mus musculus ribosomal
protein (Ke-3) gene, exons
ACAGTA, Class A, M76763, Mus musculus ribosomal
protein (Ke-3) mRNA, comple
5	.3315%	CCCTGAGTCCA	-1434325
Noted Tags = 2	Collected Tags = 2
CCCCGG, Class A, X03672, Mouse cytoskeletal mRNA
for beta-actin.
CCCCGG, Class A, J041 81, Mouse A-X actin mRNA,
complete ods.
5	.3315%	CCCTGGGTTCT	-1436408
Noted Tags = 2	Collected Tags=1
GCCCGC, Class A, J0471 6, Mouse ferritin light
chain, complete cds.
5	.3315%	GCCCGGGAATA	-2451981
Noted Tags = 1	Collected Tags = 1
AATTCA, Class A, J05277, Mouse hexokinase mRNA,
complete cds.
5	.3315%	GCGGCGGATGG	-2529851
Noted Tags = 6	Collected Tags = 5
AGACTT, Class C, A27894, Coding sequence for GBP.
AGACTT, Class A, X53067, Mouse mRNA for 14KDa lec-
tin.
AGACTT, Class A, X15986, Mouse 3′mRNA for beta-
galactoside specific lectin
AGACTT, Class A, X66532, M.musculus mRNA for L14
lectin.
AGACTT, Class A, M57470, Murine beta-galactoside
binding protein mRNA, comp
5	.3315%	GGAAGCCACTT	-2630944
Noted Tags = 0	Collected Tags = 0
5	.3315%	TAAAGAGGCCG	-3154583
Noted Tags = 1	Collected Tags = 1
TTTTGT, Class A, U67770, Mus musculus ribosomal
protein S26 (RPS26) mRNA, c
5	.3315%	TATGTCAAGCT	-3388456
Noted Tags = 1	Collected Tags=1
GGTGGA, Class A, X15962, Mouse mRNA for ribosomal
protein S12.
5	.3315%	TGGGTTGTCTA	-3849949
Noted Tags=1	Collected Tags = 1
AAAATA, Class A, X06407, Mouse mRNA for 21 kd po-
lypeptide under translation
5	.3315%	TGTAGTGTAAT	-3878596
Noted Tags=1	Collected Tags = 1
AAAGGT, Class A, X73829, M.musculus mRNA for ribo-
somal protein S8.
5	.3315%	TTCAGTGGACC	-4009606
Noted Tags = 0	Collected Tags = 0
5	.3315%	TTGGTGAAGGA	-4110377
Noted Tags = 2	Collected Tags = 0
4	.2652%	AGAAACCAATA	-525581
Noted Tags = 2	Collected Tags = 1
CGAACA, Class A, V00830, Mouse mRNA encoding epi-
dermal keratin subunit.
4	.2652%	AGTGAGGAAGA	-756233
Noted Tags = 1	Collected Tags = 0
4	.2652%	ATAATACATAA	-799025
Noted Tags = 4	Collected Tags = 0
4	.2652%	ATACTGAAGCC	-817190
Noted Tags = 1	Collected Tags = 1
CCACTT, Class A, U2891 7, Mus musculus 60S riboso-
mal protein (A52) mRNA, corn
4	.2652%	ATTCTCCAGTG	-1013039
Noted Tags = 1	Collected Tags = 0
4	.2652%	CAAACTCTCAC	-1056210
Noted Tags = 2	Collected Tags = 2
AGCGAT, Class A, X04017, Mouse mRNA for cysteine-
rich glycoprotein SPARC.
AGCGAT, Class C, M20692, Mouse osteonectin (Sparc)
gene, exon 10.
4	.2652%	CAGTCACCAAC	-1233218
Noted Tags = 0	Collected Tags = 0
4	.2652%	CCCACAAGGTA	-1380525
Noted Tags = 0	Collected Tags = 0
4	.2652%	CCTTGCTCAAT	-1568532
Noted Tags = 2	Collected Tags = 1
TAAAA, Class A, M59470, Mouse cystatin C mRNA,
complete cds.
4	.2652%	CCTTTGAGATC	-1570958
Noted Tags = 1	Collected Tags=1
ATCCAC, Class A, U78085, Mus musculus ribosomal
protein S5 mRNA, complete c
4	.2652%	CTAGTCTTTGT	-1882108
Noted Tags = 1	Collected Tags = 1
ACACAA, Class A, L31609, Mus musculus (clone
mcori-1 ck9) S29 ribosomal prot
4	.2652%	CTGAACATCTC	-1967326
Noted Tags = 1	Collected Tags = 1
CCCCTT, Class A, X15267, Mouse mRNA for acidic
ribosomal phosophoprotein PO
4	.2652%	GGCAAGCCCCA	-2689365
Noted Tags = 2	Collected Tags = 1
GCGTCT, Class A, U12403, Mus musculus Csa-19 mRNA,
complete cds.
4	.2652%	GGCCTGGCTTA	-2718333
Noted Tags = 0	Collected Tags = 0
4	.2652%	TCCCCGTACAT	-3496724
Noted Tags = 0	Collected Tags = 0
4	.2652%	TCCCTATTAAG	-3503043
Noted Tags = 0	Collected Tags = 0
4	.2652%	TCTTCTCACAA	-3661073
Noted Tags = 0	Collected Tags = 0
4	.2652%	TGGCCCAAATT	-3822608
Noted Tags = 2	Collected Tags=1
TATGCC, Class C, M11409, Mouse S16 ribosomal pro-
tein processed pseudogene.
3	.1989%	AAGGTGGAAGA	-178697
Noted Tags = 0	Collected Tags = 0
3	.1989%	ACATCATAGAT	-316196
Noted Tags = 1	Collected Tags=1
GACATC, Class A, L04280, Mus musculus ribosomal
protein (Rpl12) mRNA, compl
3	.1989%	AGGAAGGCGGC	-658026
Noted Tags = 0	Collected Tags = 0
3	.1989%	CAAGTGGAAAA	-1096193
Noted Tags = 0	Collected Tags = 0
3	.1989%	CACGCTCCCGG	-1154395
Noted Tags = 0	Collected Tags = 0
3	.1989%	CAGGCCACACA	-1217605
Noted Tags = 1	Collected Tags = 1
AGAGCC, Class A, AF0305, Mus musculus ATP synthase
beta-subunit (beta-F1 AT
3	.1989%	CCAGAACAGAC	-1343778
Noted Tags = 3	Collected Tags = 0
3	.1989%	CCCAGAGCACT	-1385032
Noted Tags = 1	Collected Tags = 1
GGGTTG, Class A, M10937, Mouse epidermal 67-kDa
type II keratin mRNA.
3	.1989%	CCCTAAACTGA	-1425529
Noted Tags = 0	Collected Tags = 0
3	.1989%	CCTGATCTTTA	-1543677
Noted Tags = 2	Collected Tags = 2
CTTCTA, Class A, X06406, Mouse mRNA for transla-
tional controlled 40 kDa pol
CTTCTA, Class A, J02870, Mouse laminin receptor
mRNA, complete cds.
3	.1989%	CCTTTAATCCC	-1568982
Noted Tags = 58	Collected Tags = 9
AGCACT, Class A, D42051, Mus musculus mRNA for
Glutamate Decarboxylase, com
AGAGGC, Class A, X79508, M.musculus (C57BL/10)
CW37 mRNA, B1 repeat.
AGCACT, Class A, U03421, Mus musculus interleukin-
11 mRNA, complete cds.
AGTTAC, Class C, U59807, Mus musculus cystatin B
(Stfb) gene, complete cds.
AGCACT, Class A, M58288, Mus musculus granulocyte
colony-stimulating factor
AGCACT, Class A, M58288, Mus musculus granulocyte
colony-stimulating factor
AGCACC, Class C, M14361, Mouse lg germline kappa-
chain V-region gene V-Ser,
AGCAAT, Class C, M93320, Mus musculus DNA frag-
ment, L1 repeat family region
AGCCCT, Class C, J00632, mouse b1 ubiquitous re-
peat (copy c) mrna and flank
AGGACT, Class A, L08394, Mus musculus betacellulin
(bcn) mRNA, complete cds
3	.1989%	CTCAACAGCAA	-1901713
Noted Tags = 0	Collected Tags = 0
3	.1989%	CTCCTGGACAC	-1931794
Noted Tags=1	Collected Tags = 1
CTGGGA, Class A, J04953, Mouse gelsolin gene, com-
plete cds.
3	.1989%	CTGGCTTTCAG	-2006995
Noted Tags = 0	Collected Tags = 0
3	.1989%	GACTTTGGAAA	-2227841
NotedTags = 6	CollectedTags = 3
ACATTT, Class A, U03419, Mus musculus alpha-1 type
I procollagen mRNA, part
ACATTT, Class C, X57981, Mouse gene for pro alpha1
(I) collagen chain (COL1
ACATTT, Class A, U08020, Mus musculus FVB/N colla-
gen pro-alpha-1 type I cha
3	.1989%	GAGCGTTTTGG	-2256891
Noted Tags = 2	Collected Tags = 1
GTCCAG, Class A, X52803, Mouse mRNA for cyclophi-
lin (EC 5.2.1.8).
3	.1989%	GATGACACCAG	-2327635
Noted Tags = 1	Collected Tags = 1
CCGCTC, Class A, U11248, Mus musculus C57BL/6J
ribosomal protein S28 mRNA,
3	.1989%	GCTGCAGTTGA	-2593529
Noted Tags = 0	Collected Tags = 0
3	.1989%	GCTGCCCTCCA	-2594261
Noted Tags = 5	Collected Tags = 0
3	.1989%	GTCTGCTGATG	-3008399
Noted Tags = 2	Collected Tags = 2
GCCAGA, Class A, X75313, M.musculus (C57BL/6) GB-
like mRNA.
GCCAGA, Class A, D29802, Mouse mRNA for G protein
beta subunit homologue, c
3	.1989%	GTGGAGGCGCC	-3050086
Noted Tags = 0	Collected Tags=0
3	.1989%	GTGGGCGTGTA	-3057389
Noted Tags = 1	Collected Tags = 1
CAACGG, Class A, M33330, Mouse insulinoma (rig)
mRNA, complete cds.
3	.1989%	TAAACCTGCTA	-3151773
Noted Tags = 0	Collected Tags = 0
3	.1989%	TATCCCACGCC	-3363942
Noted Tags = 0	Collected Tags = 0
3	.1989%	TCGGTTTCTGC	-3587962
Noted Tags = 0	Collected Tags = 0
3	.1989%	TCTCACCACCC	-3622166
Noted Tags = 0	Collected Tags = 0
3	.1989%	TGACCCCGGGA	-3691945
Noted Tags = 0	Collected Tags = 0
3	.1989%	TGCACAGTGCT	-3740392
Noted Tags = 5	Collected Tags = 4
GAGCAA, Class A, X05835, Mouse mRNA for placental
calcium-binding protein.
GAGCAA, Class A, X16190, Mouse mts1 gene.
GAGCAA, Class A, Z36947, Murine retrovirus RNA
containing parts of mts1 of
GAGCAA, Class A, D00208, Mus musculus mRNA for
pEL98 protein, complete cds.
3	.1989%	TGGTCTGGTCC	-3858102
Noted Tags = 0	Collected Tags = 0
3	.1989%	TGTAACAGGAC	-3867810
Noted Tags = 1	Collected Tags = 1
TGCTAT, Class A, X04648, Mouse mRNA for lgG1/lgG2b
Fc receptor (FcR).
3	.1989%	TTCAGGTGGTT	-4008880
Noted Tags = 1	Collected Tags = 1
TCTTCT, Class A, X73607, M.musculus mRNA for tro-
pomyosin 5 (3′UTR).
3	.1989%TTGGCTGCCCA	-4103765
Noted Tags = 1	Collected Tags = 1
GGATGT, Class C, Y08307, M.musculus mitochondrial
mRNA for ribosomal protei
2	.1326%	AAAACAGTGGC	-4842
Noted Tags = 1	Collected Tags = 1
CGGTGG, Class A, X73331, M.musculus mRNA for ribo-
somal protein L37a.
2	.1326%	AAAGCAGTGCT	-37608
Noted Tags = 0	Collected Tags = 0
2	.1326%	AAGAGGCAAGA	-141577
Noted Tags = 0	Collected Tags = 0
2	.1326%	AAGCAACAGGT	-147756
Noted Tags = 0	Collected Tags = 0
2	.1326%	AAGGTCGAGCT	-177704
Noted Tags = 0	Collected Tags = 0
2	.1326%	ACAGAACTCTT	-295392
Noted Tags = 1	Collected Tags = 1
CTCAAT, Class A, AJ0023, Mus musculus mRNA for an-
nexin VIII.
2	.1326%	ACCTTGGAAGG	-391691
Noted Tags = 1	Collected Tags = 0
2	.1326%	ACTCTTTGTTT	-491456
Noted Tags = 0	Collected Tags = 0
2	.1326%	ACTGGCTGGGC	-501674
Noted Tags = 0	Collected Tags = 0
2	.1326%	ACTTATTATGC	-511802
Noted Tags = 0	Collected Tags = 0
2	.1326%	AGAACCATTAA	-529649
Noted Tags = 0	Collected Tags = 0
2	.1326%	AGACCCTCTCA	-546677
Noted Tags = 0	Collected Tags = 0
2	.1326%	AGCAATTCAAA	-593729
Noted Tags = 6	Collected Tags = 2
CAATTA, Class C, U09637, Mus musculus domesticus
mitochondrion NADH dehydro
CAATTA, Class C, U09638, Mus musculus musculus
mitochondrion NADH dehydroge
2	.1326%	ATCAACACCGC	-853082
Noted Tags = 2	Collected Tags = 2
AACCTT, Class A, Y00703, Mouse uncoupled S49 cells
mRNA for stimulatory GTP
AACCTT, Class A, M13964, Mouse stimulatory G pro-
tein of adenylate cyclase,
2	.1326%	ATCCGAAAGAT	-876580
Noted Tags = 2	Collected Tags = 1
GAAGCT, Class A, L04128, Mus musculus ribosomal
protein L18 (rpL18) mRNA, c
2	.1326%	CACCACCACAG	-1131795
Noted Tags = 1	Collected Tags = 1
GATCAA, Class A, X05021, Murine mRNA with homolo-
gy to yeast L29 ribosomal p
2	.1326%	CACCTTGGTGC	-1146554
Noted Tags = 0	Collected Tags = 0
2	.1326%CACGGGACCAC	-1157202
Noted Tags=0	Collected Tags = 0
2	.1326%	CACTGACCTCC	-1171830
Noted Tags = 1	Collected Tags = 0
2	.1326%	CATTATGGGTG	-1298095
Noted Tags = 3	Collected Tags = 3
GCAAGA, Class A, U16818, Mus musculus UDP glucu-
ronosyltransferase (UGT1-06)
GCAAGA, Class A L02333, Murine bilirubin/phenol
family UDP glucuronosyltra
GCAAGA, Class A, L27122, Mus musculus (A-1) bili-
rubin/phenol UDP-glucuronos
2	.1326%	CCCAATGGCCC	-1379990
Noted Tags = 3	Collected Tags=3
AATAAA, Class A, X65582, M.musculus mRNA for al-
pha-2 collagen VI.
AATAAA, Class A, X62332, M.muscutus mRNA for al-
pha-2 collagen type VI, subu
AATAAA, Class A, Z18272, Mus musculus collagen al-
pha 2 chain type VI.
2	.1326%	CCCGGACTTAC	-1417714
Noted Tags = 2	Collected Tags = 0
2	.1326%	CCCGTAGCCCC	-1421910
Noted Tags = I	Collected Tags = 1
TTCCGA, Class A, M22479, Mouse tropomyosin isoform
2 mRNA, complete cds.
2	.1326%	CCTACAGTTGA	-1512185
Noted Tags = 3	Collected Tags = 3
TAATCT, Class C, K02241, Mouse alkali myosin light
chains, exons 6 and 7 co
TAATCT, Class A, K02242, Mouse alkali myosin light
chains MLC1f and MLC3f 3
TAATCT, Class C, K02243, Mouse alkali myosin light
chains MLC1f/MLC3f pseud
2	.1326%	CCTCGGAAAAT	-1533956
Noted Tags = 0	Collected Tags = 0
2	.1326%	CCTGTGTGAAA	-1555329
Noted Tags = 0	Collected Tags = 0
2	.1326%	CGCCTGCTAGC	-1669578
Noted Tags = 2	Collected Tags = 1
CAACCG, Class A, X58251 Mouse COL1A2 mRNA for pro-
alpha-2(l) collagen.
2	.1326%	CGCTGGTTCCA	-1698773
Noted Tags = 2	Collected Tags = 0
2	.1326%	CGGTTCCACCC	-1766678
Noted Tags = 0	Collected Tags = 0
2	.1326%	CTAATAAAGCC	-1847334
Noted Tags = 3	Collected Tags = 2
ACTGTG, Class A, X65922, M.musculus fau mRNA.
ACTGTG, Class A, D26610, Mouse mRNA for monoclonal
nonspecific suppressor f
2	.1326%	CTACCAGGATA	-1856141
Noted Tags = 0	Collected Tags = 0
2	.1326%	CTGCTATCCGA	-1995609
Noted Tags = 1	Collected Tags = 1
GAGAAT, Class A, X83590, M.musculus mRNA for ribo-
somal protein L5, 3′end.
2	.1326%	CTGCTTTGTGC	-1998778
Noted Tags = 2	Collected Tags = 2
TGTACA, Class A, M13227, Mouse enkephalin mRNA.
TGTACA, Class A, M55181, Mouse spermatogenic-spe-
cific proenkephalin mRNA, c
2	.1326%	CTGGGCGTGTC	-2008814
Noted Tags = 0	Collected Tags = 0
2	.1326%	CTGTAGGTGAT	-2018020
Noted Tags = 0	Collected Tags = 0
2	.1326%	CTGTGCCCTCC	-2024822
Noted Tags = 0	Collected Tags = 0
2	.1326%	CTTAAGGATCC	-2034230
Noted Tags = 0	Collected Tags = 0
2	.1326%	GAATCTGAAGT	-2153996
Noted Tags = 0	Collected Tags = 0
2	.1326%	GAATGCAGGGA	-2155689
Noted Tags = 0	Collected Tags = 0
2	.1326%	GAGGAGAAGAA	-2263073
Noted Tags = 2	Collected Tags = 1
AGCATT, Class A, Y00225, Murine mRNA for J1 pro-
tein, yeast ribosomal protei
2	.1326%	GATGCATAGTG	-2331439
Noted Tags = 1	Collected Tags = 0
2	.1326%	GATGTGACCAC	-2340946
Noted Tags = 0	Collected Tags = 0
2	.1326%	GATTTCTGTCT	-2357176
Noted Tags = 0	Collected Tags=0
2	.1326%	GCACCGAACAC	-2381842
Noted Tags=0	Collected Tags = 0
2	.1326%	GCATACGGCGC	-2410138
Noted Tags = 1	Collected Tags = 0
2	.1326%	GCATTGCATCT	-2423096
Noted Tags = 0	Collected Tags = 0
2	.1326%	GCCAAGGGTCA	-2427573
Noted Tags = 1	Collected Tags = 1
GAGGCT, Class A, L08651, Mus musculus large ribo-
somal subunit protein mRNA,
2	.1326%	GCCAAGTGGAG	-2427811
Noted Tags = 5	Collected Tags = 1
TTCCCA, Class A, M76131, Mouse elongation factor 2
(ef-2) mRNA, 3′end.
2	.1326%	GCCTAATGTAC	-2474930
Noted Tags = 1	Collected Tags = 1
ACAAAG, Class A, U93863, Mus musculus ribosomal
protein L21 mRNA, complete
2	.1326%	GCCTCGGGGGA	-2480809
Noted Tags = 0	Collected Tags = 0
2	.1326%	GCGACGCGGGC	-2496938
Noted Tags = 0	Collected Tags = 0
2	.1326%	GCGGCGGGATG	-2529935
Noted Tags = 0	Collected Tags = 0
2	.1326%	GCTCAGGATTC	-2574910
Noted Tags = 1	Collected Tags = 1
ATCTGA, Class A, X91824, M.musculus mRNA for
SPRR1a protein.
2	.1326%	GCTGGCAGACG	-2598023
Noted Tags = 0	Collected Tags = 0
2	.1326%	GCTTGCTTCCT	-2615256
Noted Tags = 1	Collected Tags = 1
GGAGCA, Class A, X89650, M.musculus mRNA for Rab7
protein.
2	.1326%	GGAAGGTGTCT	-2632632
Noted Tags = 0	Collected Tags = 0
2	.1326%	GGATTTGGCTT	-2686624
Noted Tags = 0	Collected Tags = 0
2	.1326%	GGGAGCTGTGC	-2762682
Noted Tags = 0	Collected Tags = 0
2	.1326%	GGGGAAATCGC	-2785498
Noted Tags = 1	Collected Tags = 1
CAGCTT, Class A, Z48496, M.musculus mRNA for tes-
tis-specific thymosin beta-
2	.1326%	GGGGCTCAGCC	-2792742
Noted Tags = 2	Collected Tags = 0
2	.1326%	GGTGAGCCTGA	-2853241
Noted Tags = 1	Collected Tags = 1
AGCTTG, Class A, U20611, Mus musculus thioredoxin-
dependent peroxide reduct
2	.1326%	GGTGGGACACA	-2861125
Noted Tags = 0	Collected Tags = 0
2	.1326%	GTAAGCATAAA	-2892993
Noted Tags = 0	Collected Tags = 0
2	.1326%	GTCTGGGGGGA	-3009193
Noted Tags = 0	Collected Tags = 0
2	.1326%	GTGGTAGGCTA	-3060381
Noted Tags = 0	Collected Tags = 0
2	.1326%	GTTGCTGAGAA	-3120673
Noted Tags = 2	Collected Tags = 2
GCGGCT, Class A, X75312, M.musculus (C57BL/6) QM
mRNA.
GCGGCT, Class A, M93980, Mouse 24.6 kda protein
mRNA, complete cds.
2	.1326%	GTTGGGGGGGG	-3123883
Noted Tags = 0	Collected Tags = 0
2	.1326%	TAACTGACAAT	-3176516
Noted Tags = 1	Collected Tags = 0
2	.1326%	TATACAATACA	-3346629
Noted Tags = 0	Collected Tags = 0
2	.1326%	TCCACTGTGCA	-3481317
Noted Tags=1	Collected Tags = 1
CGTGTG, Class C, L38580, Mus musculus galanin
gene, exon 6 and complete cds
2	.1326%	TCTGGACGCGG	-3645851
Noted Tags = 2	Collected Tags = 2
AAAGCA, Class C, M33988, Mouse histone H2A.1 gene,
complete cds.
CAAGCA, Class C, M37736, Mouse replication-depen-
dent histone H2A.1 gene.
2	.1326%	TGAAACACTGT	-3671164
Noted Tags = 2	Collected Tags = 2
,Class A, 086344, Mouse mRNA for Topoisomerase-in
hibitor suppressed,
T, Class A, D50465, Mouse MA-3 (apoptosis-related
gene) mRNA, complete
2	.1326%	TGACCCCGGGT	-3691948
Noted Tags = 0	Collected Tags = 0
2	.1326%	TGCCTGTGATA	-3767181
Noted Tags = 0	Collected Tags = 0
2	.1326%	TGGATCCTGAG	-3814883
Noted Tags=21	Collected Tags = 4
AACTTC, Class C, V00742, Fragment of the mouse
gene for epsilon-globin Y3 (
AACTTC, Class A, M19236, Mouse beta-globin gene.
AACTTC, Class C, J00414, Mouse beta-globin epsilon
y3 gene, exon 2.
AACTTC, Class C, M10688, Mouse beta-globin gene
with intron boundary.
2	.1326%	TGGGCAAAGCC	-3837990
Noted Tags = 0	Collected Tags = 0
2	.1326%	TGGTGACAAAA	-3858689
Noted Tags = 0	Collected Tags = 0
2	.1326%	TGTGCCAAGTG	-3904559
Noted Tags = 0	Collected Tags = 0
2	.1326%	TGTTCATCTTG	-3920767
Noted Tags = 2	Collected Tags = 1
TTTTAA, Class C, X57983, Mouse gene for pro alpha1
(III) collagen chain (CO
2	.1326%	TTCAGCTCGAG	-4007779
Noted Tags = 0	Collected Tags = 0
2	.1326%	TTGCTGCAGTG	-4094255
Noted Tags = 0	Collected Tags = 0

[0206]

TABLE 13
SAGE Analysis of MEL Mice Five Days After Wound-
ing
SearchName = C5BANK
FileName = c:\sage\data\c5data\c5bank.bag
Anchoring Enzyme = NlaIII-CATG
Tag Length = 11
DiTag Length = 24
Total Files = 67
Total Tags = 1790
Total Duplicate Dimers = 0
Tag Abundance Report
Total tags after excluding tags = 1790
Count	Percent	Tag Sequence	-Tag BaseFour Number
23	1.2849	CGGTCCAGGGA	-1758377
18	1.0955	GTGGCTCACAA	-3054865
16	.8938	GGCTTCGGTCT	-2750136
14	.7821	AGGTCGGGTGG	-711355
13	.7262	CACAAACGGTA	-1114541
13	.7262	TGGGTTGTCTA	-3849949
12	.6703	CGCCGCCGGCT	-1664424
12	.6703	CTGCTCAGGCT	-1995944
12	.6703	GCTGGCCCTTC	-2598270
11	.6145	AGGCAGACAGT	-673868
11	.6145	TTGGCTGCCCA	-4103765
10	.5586	GCCCGGGAATA	-2451981
9	.5027	AGAGCGAAGTG	-563247
9	.5027	CAGAACCCACG	-1180999
9	.5027	CATCGCCAGTG	-1271087
9	.5027	CCCCAGCCAGT	-1395020
8	.4469	AGCAGTCCCCT	-601432
8	.4469	CAAACTCTCAC	-1056210
8	.4469	CTAATAAAGCC	-1847334
8	.4469	GGCAAGCCCCA	-2689365
7	.391	CAAGGTGACAG	-1093139
7	.391	CCAGAACAGAC	-1343778
7	.391	CTGAACATCTC	-1967326
7	.391	GCCTTTATGAG	-2489571
7	.391	GGAAGCCACTT	-2630944
7	.391	GTGAACGTGCC	-3016422
7	.391	GTGGGCGTGTA	-3057389
6	.3351	AACACCAAGCT	-70696
6	.3351	CACCACCACAG	-1131795
6	.3351	CACCACCGTTG	-1131967
6	.3351	CACGCTCCCGG	-1154395
6	.3351	CCCGTGTGCTC	-1424286
6	.3351	CCTTGCTCAAT	-1566532
6	.3351	CTGCTATCCGA	-1995609
6	.3351	GAACATTGCAC	-2117522
6	.3351	GGATTTGGCTT	-2686624
6	.3351	GGGAAGGCGGC	-2755178
6	.3351	GTCTGCTGATG	-3008399
6	.3351	TCAGGCTGCCT	-3450776
6	.3351	TGGATCCTGAG	-3814883
5	.2793	CGCTGGTTCCA	-1698773
5	.2793	CTCCTGGACAC	-1931794
5	.2793	TATGTCAAGCT	-3388456
5	.2793	TCGTGATTGTG	-3597295
5	.2793	TTCAGTGGACC	-4009606
4	.2234	AAGAGGCAAGA	-141577
4	.2234	ATACTGACATT	-817232
4	.2234	CAAGTGGAAAA	-1096193
4	.2234	CCCAATGGCCC	-1379990
4	.2234	CCTACCAAGAC	-1512482
4	.2234	GATGACACCAG	-2327635
4	.2234	GATTCCGTGAG	-2348771
4	.2234	GCAGAGTGCGC	-2395034
4	.2234	GCCAAGTGGAG	-2427811
4	.2234	GCGGCGGATGG	-2529851
4	.2234	GTGGAGGCGCC	-3050086
4	.2234	TGCACAGTGCT	-3740392
4	.2234	TGGATCAGTCT	-3814584
4	.2234	TGGCTCGGTCA	-3831477
4	.2234	TGTGCCAAGTG	-3904559
4	.2234	TTCTTTGGTGA	-4062905
3	.1675	AGTGAGGAAGA	-756233
3	.1675	CACCTTGGTGC	-1146554
3	.1675	CCCTGAGTCCA	-1434325
3	.1675	CTACCACTCAA	-1855953
3	.1675	CTGAGAGAGAA	-1974817
3	.1675	CTGTAGACTGC	-2017402
3	.1675	CTGTAGGTGAT	-2018020
3	.1675	CTTGACACACA	-2065477
3	.1675	GAGTCTCCCTG	-2284895
3	.1675	GATGTGGCTGC	-2341498
3	.1675	GCCGCTAGGCC	-2464934
3	.1675	GCOTGTGGCCT	-2485912
3	.1675	GCGCCCTCCCC	-2512726
3	.1675	GGGGGCCCAGG	-2794827
3	.1675	GTGTGGGCACT	-3074632
3	.1675	GTGTTAACCAG	-3076179
3	.1675	TAAAGAGGCCG	-3154583
3	.1675	TGCTTATGATG	-3797903
3	.1675	TGGTGACAAAA	-3858689
3	.1675	TGTCAGTCTGT	-3885948
3	.1675	TTCAGCTCGAG	-4007779
2	.1117	AACAATTTGGG	-69611
2	.1117	AACAGGTTCAA	-76753
2	.1117	AAGCGCCTCAC	-157138
2	.1117	AAGGAAATGGG	-164075
2	.1117	AAGGTCTGCCT	-178072
2	.1117	AAGGTGGAAGA	-178697
2	.1117	ACAGTTCCAGA	-310601
2	.1117	ACCCTCCTCCC	-357846
2	.1117	AGAGGAAGCTG	-565407
2	.1117	AGCAGGGATCC	-600630
2	.1117	AGGAAGGCGGC	-658026
2	.1117	AGGGAGCGOTA	-690589
2	.1117	AGTGACTCTGG	-755579
2	.1117	ATTCTCCAGTG	-1013039
2	.1117	ATTTGATTAGC	-1041354
2	.1117	ATTTTCCAGTG	-1045807
2	.1117	CAATGTGGGTT	-1109680
2	.1117	CACAGACTGTG	-1122799
2	.1117	CACAGCCCACT	-1123656
2	.1117	CACCGCCAGTG	-1140015
2	.1117	CACGGCTTTCA	-1157109
2	.1117	CACGGGACCAC	-1157202
2	.1117	CAGTCACCAAC	-1233218
2	.1117	CAGTCTCTCAA	-1236433
2	.1117	CCAACGCTTTA	-1317373
2	.1117	CCACCTCCTGT	-1334652
2	.1117	CCCAGGCTGAA	-1386977
2	.1117	CCCTAAACTGA	-1425529
2	.1117	CCCTCTACAAG	-1432643
2	.1117	CCCTGGGTTCT	-1436408
2	.1117	CCCTGTGGCCG	-1437335
2	.1117	CCCTTCTTCTC	-1439710
2	.1117	CCGCCTGCAAG	-1465923
2	.1117	CCTCAGCCTGG	-1526139
2	.1117	CCTCGCACAGT	-1533004
2	.1117	CCTTTAATCCC	-1568982
2	.1117	CCTTTGTGACT	-1571720
2	.1117	CGCCTGCTAGC	-1689578
2	.1117	CTGAGAGAAAA	-1974785
2	.1117	CTGCCTCACAG	-1989907
2	.1117	CTGCGAGATTC	-1991230
2	.1117	CTGCTTTGTGC	-1998778
2	.1117	CTGTCTGAAAG	-2022915
2	.1117	CTTCTCATTTG	-2061567
2	.1117	CTTGCTCAATG	-2071823
2	.1117	CTTGGCGAGCG	-2074151
2	.1117	GAAAGTTGGCC	-2109350
2	.1117	GAACGCGACGG	-2123291
2	.1117	GACTTTGGAAA	-2227841
2	.1117	GAGTTTTCACG	-2293575
2	.1117	GCACAACTTGC	-2376186
2	.1117	GCACTGCGCAC	-2390418
2	.1117	GCCCCCGCATA	-2446925
2	.1117	GCCCCTGCGCA	-2448997
2	.1117	GCCTAATGTAC	-2474930
2	.1117	GCCTCCTCCCA	-2479957
2	.1117	GCCTTGGTGAA	-2489057
2	.1117	GCGAAGCTCAG	-2492883
2	.1117	GCGGCGCCGCA	-2529637
2	.1117	GCTCTCCAGCA	-2585893
2	.1117	GCTGCCCTCCA	-2594261
2	.1117	GCTGTGGCCAC	-2603602
2	.1117	GGCAGCCCCCT	-2696536
2	.1117	GGCTGGGGGCT	-2747048
2	.1117	GGGCCTGTGGG	-2776811
2	.1117	GGTGCCAACTA	-2855965
2	.1117	GGTGGGGGGGC	-2861738
2	.1117	GTCACAGGCAA	-2953873
2	.1117	GTCTGCGTGCC	-3008230
2	.1117	GTCTGGGGGGA	-3009193
2	.1117	GTCTGTGCCCA	-3010133
2	.1117	GTGAGCCCATT	-3024208
2	.1117	GTGGCGCACGC	-3053850
2	.1117	GTGGCTCAOAG	-3054867
2	.1117	GTGGGTGTTGG	-3059451
2	.1117	TATCTGTGCAT	-3373972
2	.1117	TATTGGCTCTG	-3402207
2	.1117	TCACTGGCCCC	-3489190
2	.1117	TCCAACTCCTT	-3475296
2	.1117	TCCCTGTGGTT	-3505072
2	.1117	TCCGGGCGAGG	-3516811
2	.1117	TCTCACCACCC	-3622166
2	.1117	TCTGCCAATTT	-3642432
2	.1117	TCTGGACGCGG	-3645851
2	.1117	TCTTCTCACAA	-3661073
2	.1117	TGAACCGTCCC	-3675862
2	.1117	TGACAGCTGCC	-3888934
2	.1117	TGACCCCGGGC	-3691946
2	.1117	TGACCCCGGGT	-3691948
2	.1117	TGAGCATCGGG	-3707755
2	.1117	TGCGTGCTGGA	-3783145
2	.1117	TGGCCCAAATT	-3822608
2	.1117	TGTAACAGGAC	-3867810
2	.1117	TGTAACTGGTC	-3868590
2	.1117	TGTGAACT1TG	-3899903
2	.1117	TGTTCATCTTG	-3920767
2	.1117	TTCAGCTCGAA	-4007777
2	.1117	TTCTGTCCTGT	-4058492
2	.1117	TTGCACCTTCT	-4081144
2	.1117	TTGGGCCAGAG	-4105507
2	.1117	TTGGTGAAGGA	-4110377
2	.1117	TTTCGTGTTGG	-4157179
2	.1117	TTTTCCACTTG	-4183167
Tags included in this report = 185
DataBase Link
Database = c:
23	1.2849%	CGGTCCAGGGA	-1758377
Noted Tags = 0	Collected Tags = 0
18	1.0055%	GTGGCTCACAA	-3054865
Noted Tags = 207	Collected Tags = 56
CCATCC, Class A, AB0046, Mus musculus mRNA for
Rab33B, complete cds.
CCATCT, Class C, 129190, Mouse MHC class I H2-D
transplantation antigen gen
CCATCT, Class A, U20225, Mus musculus adenylosuc-
cinate lyase (adi) mRNA, co
CCATCT, Class A, X93168, M.musculus mRNA for can-
nabinoid receptor 2.
CCATCT, Class A, X56974, M.musculus mRNA for ex-
ternal transcribed spacer (p
CCATCT, Class C, X52915, M. musculus gene for
H-2D(q) antigen, partial 3′c
CCATCT, Class C, V00751, Mousegene H-2Ld coding
for a transplantation anti
CCATCT, Class C, X52916, M. musculus H-2L(q) gene
for H-2L(q) antigen. 3′p
CCATCT, Class C, U06244, Mus musculus interferon
alpha/beta receptor (IFNAR
CCATCC, Class C, X64716, M.musculus NKR-P1 2 gene
for natural killer cell r
16	.8938%	GGCTTCGGTCT	-2750136
Noted Tags = 0	Collected Tags = 0
14	.7821%	AGGTCGGGTGG	-711355
Noted Tags = 1	Collected Tags = 0
13	.7262%	CACAAACGGTA	-1114541
Noted Tags = 0	Collected Tags = 0
13	.7262%	TGGGTTGTCTA	-3849949
Noted Tags = 1	Collected Tags = 1
AAAATA, Class A. X06407, Mouse mRNA for 21 kd po-
lypeptide under translation
12	.6703%	CGCCGCCGGCT	-1664424
Noted Tags = 1	Collected Tags = 0
12	.6703%	CTGCTCAGGCT	-1995944
Noted Tags = 1	Collected Tags = 1
TAGGAG, Class A, Ml 3806, Mouse keratin (epider-
mal) type I mRNA, clone pkScc
12	.6703%	GCTGGCCCTTC	-2598270
Noted Tags = 0	Collected Tags = 0
11	.6145%	AGGCAGACAGT	-673868
Noted Tags = 2	Collected Tags = 2
TGCTGT, Class A, X13661, Mouse mRNA for elongation
factor 1-alpha (EF 1-alp
TGCTGT, Class A, M22432, Mus musculus protein syn-
thesis elongation factor T
11	.6145%	TTGGCTGCCCA	-4103765
Noted Tags = 1	Collected Tags = 1
GGATGT, Class C, Y08307, M.musculus mitochondrial
mRNA for ribosomal protei
10	.5586%	GCCCGGGAATA	-2451981
Noted Tags = 1	Collected Tags = 1
AATTCA, Class A, J05277, Mouse hexokinase mRNA,
complete cds.
9	.5027%	AGAGCGAAGTG	-563247
Noted Tags = 1	Collected Tags = 1
GCGGAA, Class A, U93862, Mus musculus ribosomal
protein L41 mRNA, complete
9	.5027%	CAGAACCCACG	-1180999
Noted Tags = 2	Collected Tags = 2
ACAGTA, Class C, M76762, Mus musculus ribosomal
protein (Ke-3) gene, exons
ACAGTA, Class A, M76763, Mus musculus ribosomal
protein (Ke-3) mRNA, comple
9	.5027%	CATCGCCAGTG	-1271087
Noted Tags = 3	Collected Tags = 2
GGCAAA, Class A, M12414, Mouse apolipoprotein E
mRNA, complete cds.
GGCAAA, Class A, M73490, Mus musculus apolipopro-
tein E mRNA, 3′end.
9	.5027%	CCCCAGCCAGT	-1395020
Noted Tags = 2	Collected Tags = 1
GCCTAC, Class A, X76772, M.musculus mRNA for ribo-
somal protein S3.
8	.4469%	AGCAGTCCCCT	-601432
Noted Tags = 4	Collected Tags = 0
8	.4469%	CAAACTCTCAC	-1056210
Noted Tags = 2	Collected Tags = 2
AGCGAT, Class A, X04017, Mouse mRNA for cysteine-
rich glycoprotein SPARC.
AGCGAT, Class C, M20692, Mouse osteonectin (Sparc)
gene, exon 10.
8	.4469%	CTAATAAAGCC	-1847334
Noted Tags = 3	Collected Tags = 2
ACTGTG, Class A, X65922, M.musculus fau mRNA.
ACTGTG, Class A, D26610, Mouse mRNA for monoclonal
nonspecific suppressor f
8	.4469%	GGCAAGCCCCA	-2689365
Noted Tags = 2	Collected Tags = 1
GCGTCT, Class A, U12403, Mus musculus Csa-19 mRNA,
complete cds.
7	.391%	CAAGGTGACAG	-1093139
Noted Tags = 3	Collected Tags = 3
GCCGCT, Class A, M20632, Mouse LLRep3 protein mRNA
from a repetitive elemen
GCCGCT, Class C, M20633, Mouse LLRep3 protein
pseudogene from a repetitive
GCCGCT, Class C, M20634, Mouse LLRep3 protein
pseudogene from a repetitive
7	.391%	CCAGAACAGAC	-1343778
Noted Tags = 3	Collected Tags = 0
7	.391%	CTGAACATCTC	-1967326
Noted Tags = 1	Collected Tags = 1
CCCCTT, Class A, X15267, Mouse mRNA for acidic
ribosomal phosophoprotein PO
7	.391%	GCCTTTATGAG	-2489571
Noted Tags = 2	Collected Tags = 1
AAGAAA, Class A, X60289, M.musculus mRNA for ribo-
somal protein 524.
7	.391%	GGAAGCCACTT	-2630944
Noted Tags = 0	Collected Tags = 0
7	.391%	GTGAACGTGCC	-3016422
Noted Tags = 0	Collected Tags = 0
7	.391%	GTGGGCGTGTA	-3057389
Noted Tags = 1	Collected Tags = 1
CAACGG, Class A, M33330, Mouse insulinoma (rig)
mRNA, complete cds.
6	.3351%	AACACCAAGCT	-70696
Noted Tags = 2	Collected Tags = 2
GTCCCT, Class A, X74784, M.musculus mk2e mRNA.
GTCCCT, Class A, M24151, Mouse keratin 70 kd type
II mRNA, 3′end.
6	.3351%	CACCACCACAG	-1131795
Noted Tags = 1.	Collected Tags = 1
GATCAA, Class A, X05021, Murine mRNA with homology
to yeast L29 ribosomal p
6	.3351%.	CACCACCGTTG	-1131967
Noted Tags = 1	Collected Tags = 1
CCTTCA, Class C, M21460, Mouse surfeit locus sur-
feit 3 protein gene, exon 6
6	.3351%	CACGCTCCCGG	-1154395
Noted Tags = 0	Collected Tags = 0
6	.3351%	CCCGTGTGCTC	-1424286
Noted Tags = 0	Collected Tags = 0
6	.3351%	CCTTGCTCAAT	-1566532
Noted Tags = 2	Collected Tags = 1
TAAAA, Class A, M59470, Mouse cystatin C mRNA,
complete cds.
6	.3351%	CTGCTATCCGA	-1995609
Noted Tags = 1	Collected Tags = 1
GAGAAT, Class A, X83590, M.musculus mRNA for ri-
bosomal proteIn L5, 3′end.
6	.3351%	GAACATTGCAC	-2117522
Noted Tags = 3	Collected Tags = 2
CACACG, Class A, X12697, Mouse p2-4 mRNA for
SPARC/osteonectin (SPARC = sec
CACACG, Class C, M20691, Mouse osteonectin (Sparc)
gene, exon 9.
6	.3351%	GGATTTGGCTT	-2686624
Noted Tags = 0	Collected Tags = 0
6	.3351%	GGGAAGGCGGC	-2755178
Noted Tags = 2	Collected Tags = 1
ACGTCT, Class A, M88335, M.musculus mRNA sequence.
6	.3351%	GTCTGCTGATG	-3008399
Noted Tags = 2	Collected Tags = 2
GCCAGA, Class A, X75313, M.musculus (C57BL/6) GB-
like mRNA.
GCCAGA, Class A, D29802, Mouse mRNA for G protein
beta subunit homologue, c
6	.3351%	TCAGGCTGCCT	-3450776
Noted Tags = 7	Collected Tags = 6
TCATCT, Class A, X12812, Murine mRNA for macro-
phage ferritin heavy subunit.
TCATCT, Class C, X52561, Mouse gene for ferritin H
subunit.
TCATCT, Class A, J03941, Mouse ferritin heavy
chain (MFH) mRNA, complete cd
TTATCT, Class A, M24509, Mouse ferritin heavy
chain, complete cds.
TTATCC, Class C, M73678, Mus musculus (clone
pMHFY9) ferritin H pseudogene.
TTATCT, Class C, M73679, Mus musculus (clone
pMHFY1) ferritin H pseudogene.
6	.3351%	TGGATCCTGAG	-3814883
Noted Tags = 21	Collected Tags = 4
AACTTC, Class C, V00742, Fragment of the mouse
gene for epsiton-globin Y3 (
AACTTC, Class A, M19236, Mouse beta-globin gene.
AACTTC, Class C, J00414, Mouse beta-globin epsilon
y3 gene, exon 2.
AACTTC, Class C, M10688, Mouse beta-globin gene
with intron boundary.
5	.2793%	CGCTGGTTCCA	-1698773
Noted Tags = 2	Collected Tags = 0
5	.2793%	CTCCTGGACAC	-1931794
Noted Tags = 1	Collected Tags = 1
CTGGGA, Class A, J04953, Mouse gelsolin gene, com-
plete cds.
5	.2793%	TATGTCAAGCT	-3388456
Noted Tags = 1	Collected Tags = 1
GGTGGA, Class A. X15962, Mouse mRNA for ribosomal
protein S12.
5	.2793%	TCGTGATTGTG	-3597295
Noted Tags = 3	Collected Tags = 3
CAGAAT, Class A, U52822, Mus musculus ornithine
decarboxylase antizyme mRNA
CAGAAT, Class C, U52823, Mus musculus ornithine
decarboxylase antizyme gene
CAGAAT, Class C, U84291, Mus musculus ornithine
decarboxylase antizyme gene
5	.2793%	TTCAGTGGACC	-4009606
Noted Tags = 0	Collected Tags = 0
4	.2234%	AAGAGGCAAGA	-141577
Noted Tags = 0	Collected Tags = 0
4	.2234%	ATACTGACATT	-817232
Noted Tags = 4	Collected Tags = 0
4	.2234%	CAAGTGGAAAA	-1096193
Noted Tags = 0	Collected Tags = 0
4	.2234%	CCCAATGGCCC	-1379990
Noted Tags = 3	Collected Tags = 3
AATAAA, Class A, X65582, M.musculus mRNA for al-
pha-2 collagen VI.
AATAAA, Class A, X62332, M.musculus mRNA for al-
pha-2 collagen type VI, subu
AATAAA, Class A, Z18272, Mus musculus collagen al-
pha 2 chain type VI.
4	.2234%	CCTACCAAGAC	-1512482
Noted Tags = 0	Collected Tags = 0
4	.2234%	GATGACACCAG	-2327635
Noted Tags = 1	Collected Tags = 1
CCGCTC, Class A, U11248, Mus musculus C57BL/6J
ribosomal protein S28 mRNA,
4	.2234%	GATTCCGTGAG	-2348771
Noted Tags = 0	Collected Tags = 0
4	.2234%	GCAGAGTGCGC	-2395034
Noted Tags = 2	Collected Tags = 1
CTGCTG, Class A, Y00348, Mouse mRNA for ribosomal
protein S6.
4	.2234%	GCCAAGTGGAG	-2427811
Noted Tags = 5	Collected Tags = 1
TTCCCA, Class A, M76131, Mouse elongation factor 2
(ef-2) mRNA, 3′end.
4	.2234%	GCGGCGGATGG	-2529851
Noted Tags = 6	Collected Tags = 5
AGACTT, Class C, A27894, Coding sequence for GBP.
AGACTT, Class A, X53067, Mouse mRNA for 14KDa lec-
tin.
AGACTT, Class A, X15986, Mouse 3′mRNA for beta-
galactoside specific lectin
AGACTT, Class A, X66532, M.musculus mRNA for L14
lectin.
AGACTT, Class A, M57470, Murine beta-galactoside
binding protein mRNA, comp
4	.2234%	GTGGAGGCGCC	-3050086
Noted Tags = 0	Collected Tags = 0
4	.2234%	TGCACAGTGCT	-3740392
Noted Tags = 5	Collected Tags = 4
GAGCAA, Class A, X05835, Mouse mRNA for placental
calcium-binding protein.
GAGCAA, Class A, X16190, Mouse mts1 gene.
GAGCAA, Class A; Z36947, Murine retrovirus RNA
containing parts of mts1 of
GAGCAA, Class A, D00208, Mus musculus mRNA for
pEL9B protein, complete cds.
4	.2234%	TGGATCAGTCT	-3814584
Noted Tags = 1	Collected Tags = 1
TTAAAA, Class A, M62952, Mus musculus ribosomal
protein L19, complete cds.
4	.2234%	TGGCTCGGTCA	-3831477
Noted Tags = 6	Collected Tags = 3
CTTGGG, Class A, X13055, Murine mRNA for cytoplas-
mic gamma-actin.
CTTGGG, Class C, X13056, Murine gamma-118-actin
pseudogene.
CTTGGG, Class A, M21495, Mouse cytoskeletal gamma-
actin mRNA, complete cds.
4	.2234%	TGTGCCAAGTG	-3904559
Noted Tags = 0	Collected Tags = 0
4	.2234%	TTCTTTGGTGA	-4062905
Noted Tags = 1	Collected Tags = 0
3	.1675%	AGTGAGGAAGA	-756233
Noted Tags = 1	Collected Tags = 0
3	.1675%	CACCTTGGTGC	-1146554
Noted Tags = 0	Collected Tags = 0
3	.1675%	CCCTGAGTCCA	-1434325
Noted Tags = 2	Collected Tags = 2
CCCCGG, Class A, X03672, Mouse cytoskeletal mRNA
for beta-actin.
CCCCGG, Class A, J04181, Mouse A-X actin mRNA,
complete cds.
3	.1675%	CTACCACTCAA	-1855953
Noted Tags = 0	Collected Tags = 0
3	.1675%	CTGAGAGAGAA	-1974817
Noted Tags = 0	Collected Tags = 0
3	.1675%	CTGTAGACTGC	-2017402
Noted Tags = 0	Collected Tags = 0
3	.1675%	CTGTAGGTGAT	-2018020
Noted Tags = 0	Collected Tags = 0
3	.1675%	CTTGACACACA	-2065477
Noted Tags = 0	Collected Tags = 0
3	.1675%	GAGTCTCCCTG	-2284895
Noted Tags = 2	Collected Tags = 2
GATTGT, Class C, X59747, Mouse Sm B gene for Sm B
protein of U snRNP's, exo
GATTGT, Class A, M58761, Mouse Sm-B protein gene,
complete cds.
3	.1675%	GATGTGGCTGC	-2341498
Noted Tags = 0	Collected Tags = 0
3	.1675%	GCCGCTAGGCC	-2464934
Noted Tags = 0	Collected Tags = 0
3	.1675%	GCCTGTGGCCT	-2485912
Noted Tags = 0	Collected Tags = 0
3	.1675%	GCGCCCTCCCC	-2512726
Noted Tags = 1	Collected Tags = 1
TTGTCC, Class A, U88322, Mus musculus beta chemo-
kine Exodus-2 mRNA, complet
3	.1675%	GGGGGCCCAGG	-2794827
Noted Tags = 1	Collected Tags = 1
TGTAGA, Class C, X03059, Mouse germllne gene for
T-cell receptor J-alpha 65
3	.1675%	GTGTGGGCACT	-3074632
Noted Tags = 1	Collected Tags = 1
GGATTT, Class A, X93035, M.musculus mRNA for BRP39
protein.
3	.1675%	GTGTTAACCAG	-3076179
Noted Tags = 0	Collected Tags = 0
3	.1675%	TAAAGAGGCCG	-3154583
Noted Tags = 1	Collected Tags = 1
TTTTGT, Class A, U67770, Mus musculus ribosomal
protein S26 (RPS26) mRNA, c
3	.1675%	TGCTTATGATG	-3797903
Noted Tags = 0	Collected Tags = 0
3	.1675%	TGGTGACAAAA	-3858689
Noted Tags = 0	Collected Tags = 0
3	.1675%	TGTCAGTCTGT	-3885948
Noted Tags = 1	Collected Tags = 1
TTAACC, Class C, M21050, Mouse lysozyme M gene,
exon 4.
3	.1675%	TTCAGCTCGAG	-4007779
Noted Tags = 0	Collected Tags = 0
2	.1117%	AACAATTTGGG	-69611
Noted Tags = 0	Collected Tags = 0
2	.1117%	AACAGGTTCAA	-76753
Noted Tags = 0	Collected Tags = 0
2	.1117%	AAGCGCCTCAC	-157138
Noted Tags = 0	Collected Tags = 0
2	.1117%	AAGGAAATGGG	-164075
Noted Tags = 0	Collected Tags = 0
2	.1117%.	AAGGTCTGCCT	-178072
Noted Tags = 1	Collected Tags = 1
GAAAAC, Class A, D87896, Mus musculus phgpx mRNA
for phospholipid hydropero
2	.1117%	AAGGTGGAAGA	-178697
Noted Tags = 0	Collected Tags = 0
2	.1117%	ACAGTTCCAGA	-310601
Noted Tags = 3	Collected Tags = 3
AGTGAT, Class A, AF0234, Mus musculus HS1-asso-
ciating protein (mHAX-1s) mRN
AGTGAT, Class A, AF0234, Mus musculus HS-1-associ-
ating protein HAX-1L (mHAX
AGTGAT, Class A, X81444, M.musculus SIG-111 mRNA.
2	.1117%	ACCCTCCTCCC	-357846
Noted Tags = 3	Collected Tags = 2
CCCGCT, Class C, K01365, Mouse 18S-5.8S-28S rRNA
gene internal transcribed
CCCGCT, Class C, J00623, Mouse 18S, 5.8S, 28S rRNA
gene cluster (clone pMEB
2	.1117%	AGAGGAAGCTG	-565407
Noted Tags = 0	Collected Tags = 0
2	.1117%	AGCAGGGATCC	-600630
Noted Tags = 1	Collected Tags = 1
CCGTGC, Class A, X97490, M.musculus mRNA for PNG
protein.
2	.1117%	AGGAAGGCGGC	-658026
Noted Tags = 0	CollectedTags = 0
2	.1117%

[0207]

TABLE 14
Accession Numbers for Wound Healing Genes
X60671	Ezrin; Villin 2; NF-2 (merlin) related filament/plasma	Aff
	membrane associated protein
M26391	Rb; pp105; Relinoblastoma susceptibility-associated	Afm
	protein (tumor suppressor gene; cellcycle regulator)
U52945	TSG101 tumor suscepibility protein	Afn
U54705	Tumor suppressor maspin	A2a
D14340	ZO-1; Tight juction protein; discs-large family member,	A2d
	partially homologous to a dig-A tumor suppressor
	in Drosphila
X51983	o-ErbA oncogene; thyroid hormone receptor	A2g
J04115	o-Jun proto-onogene (transcription factor AP-1	A2i
	component)
X83974	RNA polymerase I termination factor TTF-I	A2j
X01023	c-myc proto-oncogene protein	A2l
U51866	Casin kinase II (alpha subunit)	A3n
M13845	Pim-1 proto-oncogene	A4a
X68932	c-Fms proto-oncogene (macrophage colony stimulating	A4b
	factor (CSF-1) receptor)
M84607	PDGFRa; platelet-derived growth factor alpha-receptor	A4e
U14173	Ski proto-oncogene	A4g
U18342	Sky proto-obcogene (Tyro3; Rse; Dtk)	A4h
Z50013	H-ras proto-oncogene; transforming G-protein	A5c
X13664	N-ras proto-oncogene; transforming G-protein	A5e
X81580	IGFBP-2; insulin-like growth factor binding protein 2;	A5m
	autocrine and/or paracine
X66032	Cyclin B2 (G2/M-specific)	A6d
M83749	Cyclin D2 (G1/S-specific)	A6g
Z37110	Cyclin G (G2/M-specific)	A6k
U19596	p1Bink4; cdk4 and cdk6 inhibitor	A7c
X56135	Prothymosin alpha	A7m
M36829	HSP84; heat shock 84kD protein	B1c
M36830	HSP86; heat shock 88kD protein	B1d
D78645	Glucose regulated protein, 78kDl Grp78	B1m
U34259	Golgi 4-transmembrane spanning transporter; MTP	B2d
L03529	Cl2r; coagulation factor II (thrombin) receptor	B2j
M83336	Interleukin-6 receptor beta chain; membrane gylcoprotein	B3c
	gp130
U36277	I-kappa B alpha chain	B3m
U06924	Stall; signal transducer and activator of transcription	B4d
L47650	Stat6; signal transducer and activator of transcription 6;	B4g
	IL-4 Stat; STA6
S72408	Crk adaptor protein	B5m
U28423	Inhibitor of the RNA-activated protein kinase, 58-kDa	B5i
U10671	MAPK; MAP kinase; p38	B6m
L02526	MAPKK1; MAP kinase kinase 3 (dual specificity)	B6a
	(MKK1)
D11091	PI3-K p85; phosphatidyfinositol 3-kinase regulatory	B6h
	subunit; phosphoprotein p85;
	PKC-theta; protein kinase C theta type
M60651	PDGF-signaling pathway member	B8k
X95403	Rab-2 ras-related protein	B7b
U57311	14-3-3 protein eta	B7g
M21065	IRF1; Interferon regulatory factor 1	B7k
X99063	Zyxin; LtM domain protein; alpha-actinin binding	B7n
	activity
U17162	BAG-1; bcl-2 binding protein with anti-cell death activity	C1e
U13705	Glutathione peroxidase (plasma protei); selenoprotein	C1l
X76341	Glulathione reductase	C1m
J03762	Glutathione S-transferase (microsomal)	C2a
J04696	Glutathione S-transferase Mu 1	C2b
M94335	c-Akt proto-oncogenel Rac-alpha; protein kinase B	C2k
	(PKB)
U97076	FLIP-L; apoptosis inhibitor; FLICE-like inhibitory	C3h
	protein
L28177	Gadd45; growth arrest and DNA-damage-inducible	C3j
	protein
X68193	Nm23-M2; nucleoside diphosphate kinase B; melastasis-	C4c
	reducing protein;
	c-myo-related transcription factor
D83966	Protein tyrosine phosphatase	C4g
U25995	RIP cell death protein; Fas/APO-1 (CD95) interactor,	C4j
	contains death domain
U25844	SPI3; serpin; similar to human proteinase inhibitor 6	C4l
	(placental thrombin
	inhibitor) serine proteinase inhibitor
M59376	Tumor necrosis factor receptor 1; TNFR-1	C5d
X96618	PA6 stromal protein; RAG1 gene activator	C6a
X92410	MHR23B; Rad23 UV excision repair protein homologue;	C6j
	xeroderma plgmentosum group C
	(XPC) repair complementing protein
U17698	Ablphilln-1 (abi-1) similar to HOXD3	D1a
L12721	Adipocyle diffentiation-associated protein	D1c
L36435	Basic domain/leucine zipper transcription factor	D1e
M58568	Butyrate response factor 1	D1i
U36340	CACCC Box-binding protein BKLF	D1j
X72310	DP-1 (DRTF-polipeptide 1) cell cycle regulatory	D2g
	transcription factor
J04103	Ets-2 transcription factor	D3b
X55123	GATA-3 transcription factor	D3f
U20344	Gut-specific Kruppel-like factor GKLF	D3i
X53476	HMG-14 non histone chromosomal protein	D3m
J03168	Interferon regulatory factor 2 (IRF 2)	D4l
D90176	NF-1B protein (transcription factor)	D5f
U20532	Nuclear factor related to P45 NF-E2	D5h
U53228	Nuclear hormone receptor ROR-ALPHA-1	D5i
U41628	Split hand/foot gene	D5m
M35523	Retinoic acid binding protein II cellular (CRABP-II)	D6e
U09419	Retinoid X receptor interacting protein (RIP 15)	D6g
X61753	Transcription factor 1 for heal shock gene	D6i
U51037	Transcription factor CTCF (11 zinc fingers)	D6j
X91753	Transcription factor SEF2	D7e
X57621	YB1 DNA binding protein	D7j
L13968	YY1 (UCRBP) transcriptional factor	D7k
Z31663	Activin type I receptor	E1a
U56819	C-C chamokine receptor (Monocyle chemoattractant	E1d
	protein 1 receptor (MCP-1RA)
M98547	Growth factor receptor	E2f
X13358	Glucocorticoid receptor form A	E3m
L06039	CD3f (Platelet endothelial cell adhesion molecule 1)	E6d
M27129	CD44 antigen	E6e
U43512	Dystroglycan 1	E6m
X04648	Glutamate receptor channel subunit gamma	E6n
X69902	Integrin alpha 6	E7d
Y00769	Integrin beta	E7g
J02870	Lamimin receptor 1	E7j
L24755	Bone morphogenetic protein 1	F1b
X81584	Insulin-like growth factor binding protein-6 (IGFBP 6)	F2i
X81581	Insulin-like growth factor binding protein-3 (IGFBP-3)	F2k
X81582	Insulin-like growth factor binding protein-4 (IGFBP-4)	F2l
X81583	Insulin-like growth factor binding protein-5 (IGFBP-5)	F2m
X04480	Insulin-like growth factor-IA	F3a
X12531	Macrophage inflammatory protein	F3a
U60530	Mad related protein 2 (MADR2)	F3h
M14220	Neuroleukin	F3m
U22516	Placental ribonuclease inhibitor (Angiogenin)	F4a
M13177	Transforming growth factor beta	F4f
X57413	Transforming growth factor beta 2	F4g
M13806	Cytoskeletal epidermal ketatin (14 human)	F5h
M10937	Epidermal keratin (1 human)	F5k
U04443	Non-muscle myson light chain 3	F6b
X51438	Vimentin	F6d
J04946	Angiotensin-converting enzyme (ACE) (clone ACE.5.)	F6g
M14222	Cathepsin B	F6g
X53337	Cathepsin D	F6h
X06086	Cathepsin L	F6j
M12302	Cytotoxin T lymphocyte-specific serine protease CCP	F6m
	I gene (CTLA-1)
M55617	Mast cell protease (MMCP)-4	F7b
X83536	Membrane tyoe matrix metalloproteinase	F7c
X16490	Plasminogen activator inhibitor-2	F7i
J05609	Serine protease inhibitor homolog J6	F7l
L19622	TIMP-3 tissue inhibitor of metalloproteinases-3	F7n

[0208]

TABLE 15
Differentially Expressed Genes in Healer and Non-Healer Dendritic Cells
GENE NAME	Array location	50%>
Elk-1 ets related proto-oncogene	A3a	MRL >
Pim-1 proto-oncogene	A4a	MRL >
cyclin A	A6a	MRL >
BRCA 1	A1b	MRL >
VHL	A2b	MRL >
Fli-1 ets related proto-oncogene	A3b	MRL >
BRCA2	A1c	MRL >
Fos-B	A3c	MRL >
Dcc; netrin receptor	A1d	MRL >
Fra-2	A3d	MRL >
EB1 APC binding protein	A1e	MRL >
GII oncogene	A3e	MRL >
PDGFRa	A4e	MRL >
N-ras	A5e	MRL >
ezrin	A1f	B6 >
B-myb proto-oncogene	A2f	MRL >
Jun-B	A3f	MRL >
Ret proto-oncogene	A4f	MRL >
Shc transforming adaptor protein	A5f	MRL >
Madr1	A1g	MRL >
c-ErbA oncogene	A2g	MRL >
Ski proto-oncogene	A4g	MRL >
CSF-1	A5g	MRL >
Mdm2	A1h	MRL >
c-Fos proto-oncogene	A2h	MRL >
Sky proto-oncogene	A4h	MRL >
Nf2; merlin	A1i	MRL >
c-Jun proto-oncogene	A2i	MRL >
p107; RBL1	A1j	MRL >
p130	A1k	MRL >
p53; tumor suppressor	A1l	MRL >
Fyn proto-oncogene	B5a	B6 >
Mapkk1	B6a	B6 >
Gem	B7a	B6 >
Hck tyrosine protein kinase	B5b	B6 >
Mapkk3	B6b	B6 >
Rab-2 ras related protein	B7b	B6 >
B7-2; T lymphocyte activation antigen CD86	B2g	MRL >
Mapkepk-2	B5n	B6 >
zyxin	B7n	B6 >
Craf-1	C3c	B6 >
Nm23-M2	C4c	B6 >
DAD-1	C3d	B6 >
Nur77 early response protein	C4d	B6 >
Faf1	C3e	B6 >
p55cdc	C4e	B6 >
Fas1 receptor	C3f	B6 >
PD-1 possible cell death inducer	C4f	B6 >
Adenosine A2M2 receptor	C2g	B6 >
Fas1	C3g	B6 >
protein tyrosine kphosphatase	C4g	B6 >
Adenosine A3 receptor	C2h	B6 >
MHR23A	C6i	B6 >
Blk	C2j	B6 >
c-Akt proto-oncogene	C2k	B6 >
Glutathione peroxidase	C1l	B6 >
iNOS1	C3m	B6 >
interleukin 1 receptor	C3n	B6 >
stromolysin 3	C4n	B6 >
activating transcription factor 4	D1b	MRL >
Pax6	D6b	B6 >
SRY-box containing gene 4	D7b	B6 >
adipocyte differentiation-associated protein	D1c	MRL >
transcription factor ReIB	D7c	B6 >
AT motif-binding factor ATBF1	D1d	MRL >
transcription factor NURR-1	D1g	MRL >
nuclear factor related to P45NF-E2	D5h	B6 >
Butyrate response factor 1	D1i	MRL >
CCAAT-binding transcription factor	D1k	MRL >
IRF-2	D4l	B6 >
split hand/foot gene	D5m	B6 >
Zinc finger transcription factor RU49	D7m	B6 >
SOX-3	D5n	B6 >
Zinc finger X-chromosomal protein ZFX	D7n	B6 >
activin type 1 receptor	E1a	B6 >
orphan receptor	E1b	B6 >
G-protein coupled receptor	E5c	B6 >
MCP-1RA	E1d	B6 >
CD31	E6d	B6 >
CD4 receptor	E1e	B6 >
GABA-A transporter 1	E5e	B6 >
CD44	E6e	B6 >
CD14	E6h	B6 >
CD22	E6i	B6 >
desmocollin 2	E6l	B6 >
interferon-gamma receptor	E2m	B6 >
dystroglycan 1	E6m	B6 >
ERBB-3 receptor	E1n	B6 >
interleukin-1 receptor type II	E2n	B6 >
growth hormone receptor	E3n	B6 >
VLA-3 alpha subunit	E7n	B6 >
angiogenin	F4a	B6 >
interleukin 15	F5a	B6 >
KIF3B	F6a	B6 >
non-muscle myosin light chain 3	F6b	B6 >
prepro-endothelin-3	F4c	B6 >
TGF-beta 2	F4g	B6 >
TNF-beta	F4h	B6 >
plasminogen activator inhibitor	F7h	B6 >
IGFBP-6	F2i	B6 >
uromodulin	F4i	B6 >
cathepsin H	F6i	B6 >
plasminogen activator inhibitor 2	F7i	B6 >
vascular endothelial growth factor	F4j	B6 >
cytoskeletal epidermal keratin 19	F5j	B6 >
cathepsin L	F6j	B6 >
Spi-2	F7j	B6 >
interleukin-1 beta	F4k	B6 >
collagenase type IV	F6k	B6 >
serin protease inhibitor 2.4	F7k	B6 >
follistatin	F1l	B6 >
IGFBP-4	F2l	B6 >
interleukin 10	F4l	B6 >
cytotoxic cell protease (B10)	F6l	B6 >
serine protease inhibitor homolog J6	F7l	B6 >
MIG	F1m	B6 >
neuroleukin	F3m	B6 >
Interleukin 11	F4m	B6 >
KIF1A	F5m	B6 >
CTLA1	F6m	B6 >
TIMP-2	F7m	B6 >
glial cell derived neuronal growth factor	F1n	B6 >
IGF-2	F2n	B6 >
oncostatin M	F3n	B6 >
interleukin 12 (p40) beta chain	F4n	B6 >
gelatinase B	F6n	B6 >
TIMP-3	F7n	B6 >

[0209]

TABLE 16
Segregation of Quantitative Trait Loci in Phenotype Congenic Mice
Marker	1-2-3-4-5	6-7-8-9-10	11-12-13-	14-15-17
1-185(59)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
1-228 (72)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
2-329 (45)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
2-207 (60)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
2-107 (76)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
2-113(103)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
3-310 (38)	B-B-B-B-B	H-H-H-H-B	B--B--B	B--B--H
4-149 (0)	H-H-H-H-H	H-H-H-H-S	S--S--S	S--S--
4-236(12)		U-H-		B--B--B
4-151(29)	H-S-B-U-H	H-B-H-H-H	H--S--S	H--H--B
4-306(51)		U-B-H-H-H	H--S--U	S--S--B
4-127(78)	U-B-U-U-U	U-U-B-U-B	B--B--B	B--B--B
5-255(34)	H-U-S-U-S	S-S-H-H-S	H--H--H	S--S--B
5-215(71)	S-U-S-U-U	U-S-U-S-H	H--S--S	S--S--B
7-228 (19)	H-B-B-U-H	B-B-H-B-H	B--H--B	B--B--B
7-220(52)	H-S-B-S-B	B-H-B-H-S	B--S--S	H--H--H
7-237 (53)	H-S-B-H-B	B-H-B-H-S	H--S--S	H--H--H
8-211(49)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
8-166	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
9-297(15)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
9-207(33)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
10-106(17)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
10-198(40)	H-H-B-B-B	B-H-H-H-S	H--H--S	H--H--B
10-233(62)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
11-74(0)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
11-235(20)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
11-245(43)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
11-48(77)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
12-158(38)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
12-132(52)	B-B-B-B-B	B-B-B-B-B	B--B--B	H--H--B
12-233(52)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
13-135(10)	B-B-B-B-B	B-B-B-B-B	H--H--H--	B--H--H
13-115(11)	B-B-B-B-B	B-B-B-B-B	H--H--H	B--H--H
13-116(13)	B-B-B-B-B	B-B-B-B-B	H--H--H	B--H--H
13-60 (16)	B-B-B-S-H	B-S-S-H-B	H--H--H	B--H--H
13-245 (30)	B-B-B-S-H	B-U-S-H-B	H--H--H	B--H--H
13-139 (32)	H-H-S-H-B	B-S-S-H-H	H--S--H	S--S--H
13-NDS1(32)	H-H-S-H-B	B-S-S-H-H	H--S--H	S--S--H
13-13(35)	H-H-S-H-B	B-S-S-H-H	H--S--H	S--S--H
13-184(35)	H-H-S-H-B	B-S-S-H-H	H--S--H	S--S--H
13-122(36)	H-H-S-U-B	B-S-S-H-B	H--S--H	S--S--H
13-124(37)	H-H-S-U-B	B-S-S-H-B	H--S--H	S--S--H
13-142(37)	H-H-S-H-B	B-S-S-H-B	H--S--H	S--S--H
13-26 (38)	H-H-S-H-B	B-S-S-H-B	H--S--H	S--S--U
13-231 (39)	H-H-S-B-B	B-S-U-H-B	H--S--H	S--S--H
13-11 (40)	H-H-S-U-B	B-S-U-H-U	H--S--H	S--S--H
13-254 (40)	H-H-S-H-B	B-S-S-H-B	H--S--H	S--S--H
13-191 (45)	H-H-S-U-B	B-S-S-S-B	H--S--H	S--S--H
13-27 (42)	H-H-S-U-B	B-S-S-S-B	B--H--H	H--B--U
13-144(48)	H-H-S-H-B	B-S-S-S-B	B--H--H	H--B--B
13-148(59)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--U
13-129(60)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
13-260 (65)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
14-110(3.5)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
14-121(17)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
15-230(28)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
15-189(49)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
15-242(56)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
15-244(56)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
16-32(2)	B-B-B-B-B	B-B-H-H-B	B--B--B	B--B--B
16-39(29)	S-H-H-S-H	H-H-S-H-H-	B--H--H	H--H--B
18-158(16)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
18-123(31)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B
19-101(26)	B-B-B-B-B	B-B-B-B-B	B--B--B	B--B--B

REFERENCES

[0210] 1. Gross, J. Getting to mammalian wound repair and amphibian limb regeneration: a mechanistic link in the early events. Wound Repair and Regeneration 4,190-202, 1996.

[0211] 2. Stocum, D. L. Tissue restoration: approaches and prospects. Wound Repair and Regeneration. 4, 3-15, 1996.

[0212] 3. Borgens, R. B. Mice regrow the tips of the foretoes. Science 217,747-50, 1982.

[0213] 4. Goss, R. J. Problems of antlerogenesis. Clin. Orthopaedics 69,227-38, 1970.

[0214] 5. Goss, R. J. and Grimes, L. N. Epidermal downgrowths in regenerating rabbit ear holes. J. Morphology 146, 533-42, 1975.

[0215] 6. Fausto, N. Hepatic regeneration. In Hepatology: a textbook in liver disease, 2nd edition (eds. Zakim, D. and Boyer, T. D.), pp. 49-65 Saunders, Philadelphia, 1990.

[0216] 7. Michalopoulos, G. K. and DeFrances, M. C. Liver Regeneration. Science 276, 60-66, 1997.

[0217] 8. Folkman, J. and Klagsbrun, M. Angiogenic factors. Science 235, 442-447,1987.

[0218] 9. Potten, C. S. and Morris, R. J. Epithelial stem cells in vivo. In Stem Cells. (eds. Lord, B. I. and Dexter, T. M.) pp. 45-62, The Company of Biologists Limited, Cambridge, 1988.

[0219] 10. Martin, P. Wound Healing—Aiming for perfect skin regeneration. Science 276, 75-81, 1997.

[0220] 11. Spangrude, G. J., Heimfeld, S., Weisman I. L. Purification and characterization of mouse hematopoietic stem cells. Science 241, 58-62,1988.

[0221] 12. Wornom, I. L. and Buchman, S. R. Bone and cartilaginous tissue. In Wound healing: biochemical and clinical aspects. (eds. Cohen, I. K., Diegelmann, R. F. and Lindblad, W. J.) pp.356-83, Saunders, Philadelphia, 1992.

[0222] 13. Murphy, E. D. and Roths, J. B. Autoimmunity and lymphoproliferation: Induction by mutant gene 1pr and acceleration by a male-associated factor in strain BXSB. In Genetic Control of Autoimmune Disease. (eds. Rose, N. R., Bigazzi, P. E., and Warner, N. L).pp. 207-220, Elsevier, New York, 1979.

[0223] 14. Cohen, P. L. and Eisenberg, R. A. Lpr and gld: Single Gene models of Systemic Autoimmunity and Lymphoproliferartive disease. Annu. Rev. Immunol. 9,243-69,1991.

[0224] 15. Theofilopoulos, A. N. Immunologic genes in mouse lupus models. In The Molecular Pathology of Autoimmune Diseases. (eds. Bona, C., Siminovitch, K. A., Zanetti, M. and Theofilopoulos, A. N.) pp. 281-316, Harwood Academic Publishers, Langhorne, 1993.

[0225] 16. Watanabe-Fukunaga, R., Brannan, C., Copeland, N. G., Jenkins, N. A. and Nagata, S. Lymphoproliferation disorder in mice is explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-316, 1992.

[0226] 17. Watson, M. L., et. al. Genetic analysis of MRL-1pr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease modifying loci. J. Exp. Med. 176, 1645-1656, 1992.

[0227] 18. Russell, P. S. and Billingham, R. E. Some aspects of the repair process in mammals. Prog. Surg. 2,1-72, 1962.

[0228] 19. Chalkley, D. T. The cellular basis of limb regeneration. In Regeneration in vertebrates. (ed. Thornton, C. S.) pp.34-58, Univ. of Chicago Press, Chicago, 1959.

[0229] 20. Simon, H-G, Kittappa, R., Khan, P. A., Tsilfidis,C., Liversage, R. A., and Oppenheimer, S. A novel family of T-box genes in urodele amphibian limb development and regeneration: candidate genes in vertebrate forelimb/hindlimb patterning. Development 124:1355-1366,1997.

[0230] 21. Muneoka, K., Fox, W. F., and Bryant, S. V. Cellular contribution from dermis and cartilage to the regenerating limb blastema in axolotls. Developmental Biology 116: 256-60, 1986.

[0231] 22. Carrel, A. and Hartmann, A. Cicatrization of wounds. I. The relation between the size of the wound and the rate of its cicatrization. J. Exp. Med. 24: 429-450, 1916.

[0232] 23. Adachi, M., Watanabe-Fukunaga, R. and Nagata, S. Aberrant transcription caused by the insertion of an endogenous retrovirus in an apoptosis gene. PNAS 90,1756-1760,1993.

[0233] 24. Costa, O. and Monier, J. C. Anithistone antibodies detected by microELISA and immunoblotting in mice with lupus-like syndrome (MRL/1, MRL/n, PN, AND NZB strains). Clin. Immunol. Immunopath. 40, 276-282,1986.

[0234] 25. Clark, R. A. F. Wound Repair: Overview and general considerations. In The Molecular and Cellular Biology of Wound Repair. (ed.Clark, R.) pp. 3-35, Plenum Press, New York, 1996.

[0235] 26. Yamada, K. M. and Clark, R. A. F. Provisional Matrix In The Molecular and Cellular Biology of Wound Repair. (ed.Clark, R.) pp.51-82, Plenum Press, New York, 1996.

[0236] 27. Stocum, D. L. The urodele limb regeneration blastema. Determination and organization of the morphogenetic field. Differentiation. 27,13-28, 1984.

[0237] 28. Mustoe, T. A., Pierce, G. F., Morishima, C. and Deuel, T.F. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J. Clin. Invest. 87, 694-703, 1991.

[0238] 29. Pierce, G. F., et. al. Platelet-derived growth factor (BB homodimer), transforming growth factor-B 1, and basic fibroblast growth factor in dermal wound healing: Neovessel and matrix formation and cessation of repair. Am. J. Pathol. 140, 1375-1388, 1992.

[0239] 30. Uh1, E., et al. Basic fibroblast growth factor accelerates wound healing in chronically ischaemic tissue. Br. J. Surg. 80, 977-980, 1993.

[0240] 31. McBrearty, B. A., Desquenne Clark, L., Zhang, X-M, Blankenhorn, E. P., and Heber-Katz,E. Genetic analysis of a mammalian wound healing trait. Proc. Natl. Acad. Sci. U.S.A., in press.

[0241] 32. Ragsdale, C. W., Gates, P., Hill, D. S. and Brockes, J. P. Delta retinoic acid receptor isoform d1 is distinquished by its exceptional N-terminal sequence and abundance in the limb regeneration blastema. Mechanisms of Development. 40,99-112, 1992.

[0242] 33. White, J. A., Boffa, M. B., Jones, B. and Petkovich, M. A zebrafish retinoic acid expressed in the regenerating caudal fin. Development. 120, 1861-1872, 1994.

[0243] 34. Chernoff, E. A. G. and Stocum, D. Developmental aspects of spinal cord and limb regeneration. Dev. Growth Diff 37,133-47, 1995.

[0244] 35. Joseph, J., and Dyson, M. (1966) Brit. J. Surg. 53, 372-380.

[0245] 36. Clark, L. D., Clark, R. K., and Heber-Katz, E. (1998) Clin Immunol Immunopath, 88, 34-45.

[0246] 37. Murphy E. D. (1981) in Immunological defects in laboratory animals Vol.2, eds. Gershwin, M. E., Merchant, B. (New York and London), pp 143-73.

[0247] 38. Dietrich, W. F. et al. (1994) Nature Genetics 7, 220-245.

[0248] 39. Manly, K. F. (1993) Mammalian Genome 4, 303-313.

[0249] 40. Doerge, R. W., and Churchill, G. A. (1996) Genetics 142, 285-294.

[0250] 41. Churchill, G. A., and Doerge, R. W. (1994) Genetics 138, 963-971.

[0251] 42. Wright, S. in Quantitative Genetics (1952) eds. Reeve, E. C. and Waddington, C. H.) (HMSO, London), pp. 5-41.

[0252] 43. Hartl, D. L. in Basic Genetics (1991) (Jones and Bartlett, Boston), pp. 218-220.

[0253] 44. Lander, E. S., and Krugylak, L. (1995). Nature Genetics 11, 241-247.

[0254] 45. Cheveraud, J. M., and Routman, E. J. (1995) Genetics 139, 1455-61.

[0255] 46. Frankel, W. (1995) Trends Genet 11, 471-477.

[0256] 47 . Simon, M I, Strathmann, M P, and Gautum, N. (1991) Science 252, 802-808.

[0257] 48. Bryant, S. V. and Gardinar, D. M. (1997) in Metamorphosis and regeneration: Keys to tissue Regeneration, p. 12.

[0258] 49. Reginelli, A. D., Wang,Y-Q, Sassoon, D., and Muneoka, K. (1995) Development 121, 1065-1076.

[0259] 50. Chuong, C. M., Widelitz, R. B., Ting-Berreth, S., and Jiang., T. X. (1996) J. Invest. Derm. 107, 639-646.

[0260] 51. Ron, D., Reich,R., Chedid, M., Lengel, C., Cohen, O. E., Chan, A. M. Neufeld, G., Miki, T., and Tronick, S. R. (1993) J. Biol.Chem. 268, 5388-5394.

[0261] 52. Percrino, L. T., Lo, D. C., Brockes, J. P. (1994) Development 20, 325-333.

[0262] 53. Sucov, H. M. and Evans, R. M. (1995) Molecular Neurobiology 10, 1969-184.

[0263] 54. Shah, M., et al. (1995) J. Cell Sci. 108, 15-17.

Claims

1. A method of identifying a gene involved in enhanced wound healing, comprising the steps of: identifying DNA microsatellite markers which can distinguish a first and a second mouse strain, wherein the first mouse strain is a healer mouse strain and wherein the second mouse strain is not a healer mouse strain; and identifying microsatellite markers which segregate with enhanced wound healing in progeny of the first and second mouse strains, whereby a chromosomal locus which contains at least one gene involved in enhanced wound healing is identified.

2. The method of claim 1 wherein the first mouse strain is an MRL mouse.

3. The method of claim 1 wherein the first mouse strain is a progeny of a healer mouse and a non-healer mouse.

4. The method of claim 3 wherein the healer mouse is an MRL mouse.

5. The method of claim 1 wherein the first mouse strain is created by: performing a cross between a first mouse of a healer strain and a mouse of a non-healer strain to form an F1 mouse; and performing a back-cross between the F1 mouse and a second mouse of the healer strain.

6. The method of claim 1 wherein the first mouse strain is created by: performing a cross between a mouse of a healer strain and a first mouse of a non-healer strain to form an F1 mouse; and performing a back-cross between the F1 mouse and a second mouse of the non-healer strain.

7. The method of claim 1 wherein the first mouse strain is created by: performing a cross between a mouse of a healer strain and a mouse of a non-healer strain to form F1 progeny mice; and performing a cross between two of the F1 progeny mice to form F2 progeny mice.

8. The method of claim 1 wherein the first mouse strain is created by successive repetition of the steps of claim 5.

9. The method of claim 1 wherein the first mouse strain is created by successive repetition of the steps of claim 6.

10. The method of claim 1 wherein the first mouse strain is a progeny of a first non-healer mouse and a second non-healer mouse.

11. The method of claim 1 wherein the first mouse strain comprises at least one quantitative trait locus selected from the group consisting of the quantitative trait loci shown in Tables 2 , 9, and 16, wherein the first mouse exhibits an enhanced healing response to a wound compared to a second mouse which does not comprise the at least one chromosomal locus, wherein the first mouse is not an MRL mouse.

12. A method of treating a wound in a mammal, comprising the step of: administering to a mammal with a wound a reagent which specifically binds to an expression product of a gene whose expression is decreased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse, whereby expression of the gene is decreased.

13. The method of claim 12 wherein the gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13 whose expression is decreased after wounding.

14. The method of claim 12 wherein the gene is selected from the group consisting of msx2 and RARg.

15. The method of claim 12 wherein the expression product is an mRNA.

16. The method of claim 15 wherein the reagent is an antisense oligonucleotide.

17. The method of claim 12 wherein the expression product is a protein.

18. The method of claim 17 wherein the reagent is an antibody.

19. The method of claim 12 wherein the wound is contacted with the reagent.

20. The method of claim 12 further comprising the step of suppressing T cell function in the mammal.

21. A method of treating a wound in a mammal, comprising the step of: administering to a mammal with a wound an expression product of a gene whose expression is increased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse, whereby the level of the expression product in the wound is increased.

22. The method of claim 21 wherein the gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13 whose expression is increased after wounding.

23. The method of claim 21 wherein the gene is selected from the group consisting of msx2 and RARg.

24. The method of claim 21 wherein the expression product is provided using a Polynucleotide which encodes the expression product.

25. The method of claim 21 wherein the wound is contacted with the expression product.

26. The method of claim 21 further comprising the step of suppressing T cell function in the mammal.

27. A method of restoring function after nerve injury in a mammal, comprising the step of: administering to a mammal with a nerve injury a reagent which specifically binds to an expression product of a gene whose expression is decreased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse, whereby expression of the gene is decreased.

28. The method of claim 27 wherein the expression product is an mRNA.

29. The method of claim 28 wherein the reagent is an antisense oligonucleotide.

30. The method of claim 27 wherein the expression product is a protein.

31. The method of claim 30 wherein the reagent is an antibody.

32. The method of claim 27 wherein the gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13 whose expression is decreased after wounding.

33. The method of claim 27 wherein the gene is selected from the group consisting of msx2 and RARg.

34. The method of claim 27 further comprising the step of suppressing T cell function in the mammal.

35. The method of claim 27 wherein the nerve injury is contacted with the expression product.

36. A method of restoring function after nerve injury in a mammal, comprising the step of: administering to a mammal with a nerve injury an expression product of a gene whose expression is increased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse, whereby the level of the expression product in the wound is increased.

37. The method of claim 36 wherein the gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13 whose expression is increased after wounding.

38. The method of claim 36 wherein the gene is selected from the group consisting of msx2 and RARg.

39. The method of claim 36 further comprising the step of suppressing T cell function in the mammal.

40. The method of claim 36 wherein the nerve injury is contacted with the expression product.

41. The method of claim 36 wherein the expression product is provided using a polynucleotide which encodes the expression product.

42. A method of treating a wound in a mammal, comprising the step of: administering to a mammal with a wound a cell or a cellular extract obtained from a healer mouse, whereby healing of the wound in the mammal is enhanced.

43. The method of claim 42 wherein the transferred cell is selected from the group consisting of macrophages, fetal liver cells, dendritic cells, stem cells, peripheral blood leukocytes, and bone marrow cells.

44. The method of claim 42 further comprising the step of suppressin g T cell function in the mammal.

45. A method of treating a wound in a mammal, comprising the step of: administering to a mammal with a wound a cell in which expression of a wound healing gene has been altered, whereby healing of the wound in the mammal is enhanced.

46. The method of claim 45 wherein the wound healing gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13.

47. The method of claim 45 wherein the wound healing gene is selected from the group consisting of msx2 and RARg.

48. The method of claim 45 further comprising the step of suppressing T cell function in the mammal.

49. A healer mouse having at least one quantitative trait locus selected from the group consisting of the quantitative trait loci shown in Tables 2, 9, and 16, wherein the healer mouse exhibits an enhanced healing response to a wound compared to a mouse which does not have the at least one chromosomal locus, wherein the healer mouse is not an MRL mouse.

50. The healer mouse of claim 49 which is created by: performing a cross between a mouse of a healer strain and a mouse of a non-healer strain.

51. The healer mouse of claim 49 which is created by: performing a cross between a mouse of a first non-healer strain and a mouse of a second non-healer strain.

52. The healer mouse of claim 49 which is created by: performing a cross between a mouse of a healer strain and a mouse of a non-healer strain to form F1 progeny mice; and performing a cross between two of the F1 progeny mice to form F2 progeny mice.

53. The healer mouse of claim 49 which is created by: performing a cross between a mouse of a healer strain and a first mouse of a non-healer strain to form an F1 mouse; and performing a back-cross between the F1 mouse and a second mouse of the non-healer strain.

54. The healer mouse of claim 49 which is created by: performing a cross between a first mouse of a healer strain and a mouse of a non-healer strain to form an F1 mouse; and performing a back-cross between the F1 mouse and a second mouse of the healer strain.

55. The healer mouse of claim 49 which is created by successive repetition of the steps of claim 48.

56. The healer mouse of claim 49 which is created by successive repetition of the steps of claim 49.

57. The healer mouse of claim 49, wherein a hole punched in an ear of the healer mouse closes at least 70% within 60 days after punching.

58. The healer mouse of claim 49 wherein the enhanced healing response comprises regeneration of a wounded tissue.

59. The healer mouse of claim 49 wherein the wound is a neural tissue wound.

60. The healer mouse of claim 59 wherein the neural tissue is spinal cord.

61. The healer mouse of claim 59 wherein the neural tissue is optic nerve.

62. The healer mouse of claim 49 which is a male mouse.

63. The healer mouse of claim 49 which is a female mouse.

64. The healer mouse of claim 49 which is T cell deficient.

65. A preparation comprising a fraction of an extract of a tissue of a healer mouse, wherein the preparation alters a biological property of a model of wound healing.

66. The preparation of claim 65 wherein the biological property is selected from the group consisting of enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell movement, cell adhesion, cell replication, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability.

67. A preparation comprising cells of a healer mouse, wherein the preparation alters a biological property of a model of wound healing.

68. The preparation of claim 67 wherein the biological property is selected from the group consisting of enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell movement, cell adhesion, cell replication, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability.

69. The preparation of claim 67 wherein the cells are selected from the group consisting of macrophages, fetal liver cells, dendritic cells, stem cells, peripheral blood leukocytes, and bone marrow cells.

70. A method of identifying a factor involved in enhanced wound healing, comprising the steps of: contacting a model of wound healing with a fraction of a composition selected from the group consisting of serum, a fraction of serum, an extract of at least one healer mouse tissue, and a fraction of an extract of at least one healer mouse tissue; assaying a property of the model of wound healing, wherein a fraction of a composition which alters the property of the model of wound healing is identified as comprising a factor involved in enhanced wound healing.

71. The method of claim 70 wherein the model of wound healing is an in vitro model.

72. The method of claim 70 wherein the model of wound healing is an in vivo model.

73. The method of claim 70 wherein the property of the model of wound healing is selected from the group consisting of enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell movement, cell adhesion, cell replication, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability.

74. A method of screening test compounds for the ability to enhance wound healing, comprising the steps of: contacting a healer model of wound healing with a test compound, wherein the healer model comprises cells of a healer mouse; and measuring the effect of the test compound on a biological property associated with wound healing in the healer model, wherein a test compound which enhances the biological property of the healer model is identified as a potential factor for enhancing wound healing.

75. The method of claim 74 wherein the biological property of the healer model is selected from the group consisting of enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell movement, cell adhesion, cell replication, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability.

76. The method of claim 74 wherein the healer model is an in vitro model.

77. The method of claim 74 wherein the healer model is an in vivo model.

78. The method of claim 74 further comprising the step of comparing the effect of the test compound on the biological property of the healer model with a biological property of a non-healer model of wound healing, wherein a test compound which alters the biological property of the non-healer model to resemble the biological property of the healer model is identified as a potential factor for enhancing wound healing.